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SUMMARY 
 
               The goal of this thesis project was to construct a cell line carrying a SARS 
coronavirus (SARS-CoV) replicon, which is incapable of producing viral particles. First, 
partial SARS-CoV cDNAs and antibiotic resistance/reporter gene DNA were generated and 
assembled in vitro to produce the replicon transcription template, which was then transcribed 
in vitro to generate the replicon RNA. The latter was introduced into a mammalian cell line 
and the transfected cells were selected for by antibiotic application. For the antibiotic-resistant 
cell lines thus generated, the expression of reporter gene was monitored repeatedly using 
fluorescent microscopy and flow cytometry. Replicon and sub-replicon RNAs were detected 
by northern blot analysis, RT-PCR and DNA sequencing. The results of these analyses showed 
that the SARS-CoV replicon RNA replicated and persisted in the cells for at least six weeks. 
The replicon cell lines thus developed could be useful for anti-SARS drug screening. 
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INTRODUCTION & LITERATURE REVIEW 
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1.1 Introduction 
Severe acute respiratory syndrome (SARS) is a potentially fatal atypical pneumonia 
that arose in Guangdong Province of the People’s Republic of China in November 2002 and 
spread to 26 countries on five continents, causing large scale outbreaks in Hong Kong, 
Singapore and Toronto in early 2003 (Peiris et al., 2003b).  SARS was recognized in late 2002, 
and by the end of the outbreak in July 2003 more than 8000 cases and 774 deaths were 
attributed to SARS worldwide (Kuiken et al., 2003). This outbreak has had a profound impact 
on public health and economies worldwide and reminded the danger of emerging infectious 
diseases in densely populated societies. 
The etiologic agent of SARS was identified as a novel coronavirus (SARS-CoV) 
(Peiris et al., 2003a; Drosten et al., 2003; Ksiazek et al., 2003; Poutanen et al., 2003; Rota et al., 
2003; Marra et al., 2003). The genome sequence of SARS-CoV does not resemble more 
closely any of the three recognized groups of coronaviruses. Soon after the disease was 
recognized, the ability to experimentally infect and induce interstitial pneumonitis in 
Cynomolgus macaques with SARS-CoV was demonstrated, thus fulfilling Koch’s postulates 
and confirming that SARS-CoV was the causative agent of SARS (Fouchier et al., 2003; 
Kuiken et al., 2003) 
             The origin of the SARS-CoV has been the subject of intense speculation despite 
closely related coronaviruses that were recovered from civet cats and other animals in 
Guangdong Province, suggesting the SARS-CoV could have originated from such animals and 
implicating SARS as a zoonosis disease (Guan et al., 2003). Most likely, this newly recognized 
pathogen has crossed the species barrier from small animals, such as masked palm civets, to 
humans (Guan et al., 2003; Martina et al., 2003).  
Despite the 2002 /2003 SARS epidemic being eventually controlled by case isolation, 
there is still neither an effective treatment for SARS nor an efficacious vaccine to prevent 
infection (Peiris et al., 2003b). The significant morbidity and mortality, and potential for 
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reemergence, make it necessary to develop effective methods to treat and prevent the disease. 
One important aspect in the fight against SARS is to develop antiviral agents that can 
specifically inhibit the RNA synthesis of SARS-CoV.  
 
1.2 Classification of SARS-CoV 
The severe acute respiratory syndrome (SARS) is due to an infection with a novel 
coronavirus which was first identified by researchers in Hong Kong, the United States, and 
Germany (Peiris et al., 2003a; Drosten et al., 2003; Ksiazek et al., 2003; Poutanen et al., 2003; 
Rota et al., 2003; Marra et al., 2003). The virus was then termed SARS-associated coronavirus 
and acronymized as SARS-CoV. 
Coronaviruses (order Nidovirales, family Coronaviridae, genus Coronavirus) are a 
group of viruses with large, enveloped and crown-like virions, and positive-sense single-
stranded RNA genomes (Siddell et al., 1983).  The genomes of coronaviruses range in length 
from 27 to 32 kb, the largest of any of the known RNA viruses. The virions measure between 
about 100 and 140 nanometers in diameter. Most but not all viral particles display the 
characteristic appearance of surface projections, giving rise to the virus family’s name (corona, 
Latin = crown).  Coronaviruses share the characteristic 3’ co-terminal, nested-set structure of 
the sub-genomic RNAs, unique RNA synthesis strategy, genome organization, nucleotide 
sequence homology, and the properties of their structural proteins (Cavanagh et al., 1995).  
             The coronaviruses are classified into three groups based on genetic and serological 
relationships. Group 1 contains the porcine epidemic diarrhea virus (PEDV), porcine 
transmissible gastroenteritis virus (TGEV), canine coronavirus (CCoV), feline infectious 
peritonitis virus (FIPV), human coronavirus 229E (HCoV-229E), and the recently identified 
human coronavirus NL63 (HCoV-NL63). Group 2 contains the murine hepatitis virus (MHV), 
bovine coronavirus (BCoV), human coronavirus OC43 (HCoV-OC43), rat sialodacryoadenitis 
virus (SDAV), porcine hemagglutinating encephalomyelitis virus (PHEV), canine respiratory 
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coronavirus (CRCoV), and equine coronavirus (ECoV). Group 3 contains the avian infectious 
bronchitis virus (IBV) and turkey coronavirus (TCoV). There are more than a dozen known 
coronaviruses affecting different animal species; while group I and II coronaviruses affect 
various mammals, those in group III infect birds. SARS-CoV seems to be the first coronavirus 
that causes severe disease in humans (Berger et al., 2004).  
The genome sequence reveals that SARS-CoV is only moderately related to other 
known coronaviruses, including two human coronaviruses, HCoV-OC43 and HCoV-229E. 
(Drosten et al., 2003; Peiris et al., 2003a; Marra et al., 2003; Rota et al., 2003). The SARS-
CoV appears to be neither a mutant of a known coronavirus nor a recombinant between known 
coronaviruses (Holmes et al., 2003a). Some proposed that SARS-CoV defines a fourth lineage 
of coronavirus (Group IV) (Marra et al., 2003) while others suggested that it may be an early 
split-off from the group 2 lineage (Snijder et al., 2003). The sequence analysis of SARS-CoV 
seems to be consistent with the hypothesis that it is an animal virus for which the normal host 
is still unknown and that has recently either developed the ability to infect humans or has been 
able to cross the species barrier (Ludwig et al., 2003). As the virus passes through human 
beings, SARS-CoV is apparently maintaining its consensus genotype and thus seems well-
adapted to the human host (Ruan et al., 2003). 
 
1.3 Structure of SARS-CoV 
Electron micrographs of SARS-CoV particles propagated in Vero E6 cells are shown 
in Figure 1. The virions appear as spherical, enveloped particles with club shaped surface 
projections and diameters between 60 and 130 nm.  
A general structural model of coronavirus virions is shown in Figure 2. The virions are 
spherical enveloped particles about 100 to 120 nm in diameter. Inside the virion is a single-
stranded, positive-sense genomic RNA 27 to 32 kb in size (Boursnell et al., 1987; Eleouet et al., 
1995; Herold et al., 1993). The viral nucleocapsid phosphoprotein interacts with the positive 
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sense RNA genome and form a helical nucleocapsid (Macnaughton et al., 1978; Sturman et al., 
1980). A corona of large, distinctive spikes in the envelope makes possible the identification of 
coronaviruses by electron microscopy. The virus core is enclosed by a lipoprotein envelope, 
which is formed during virus budding from intracellular membranes (Griffiths et al., 1992; 
Oshiro et al., 1971; Tooze et al., 1985). Two types of prominent spikes line the outside of the 
virion. The long spikes (20 nm), which consist of the spike glycoprotein, are present on all 
coronaviruses, the short spikes, which consist of the hemagglutinin-esterase glycoprotein, are 
present in only some coronaviruses. The envelope also contains the membrane glycoprotein, 
which spans the lipid bilayer three times (Machamer et al., 1993; Machamer et al., 1990; 
Machamer et al., 1987). The spike glycoprotein, bind to receptors on host cells and fuse the 
viral envelope with host cell membranes (Luo et al., 1998). 
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Figure 1. Electron micrographs of SARS- CoV Particles Propagated in Vero E6 Cells. (A) A 
thin-section view of viral nucleocapsids aligned along the membrane of the rough endoplasmic 
reticulum (arrow) as particles bud into the cisternae. Enveloped virions have surface 
projections (arrowhead) and an electron-lucent center. Directly under the viral envelope lies a 
characteristic ring formed by the helical nucleocapsid, often seen in cross section. (B) A stain-
penetrated coronavirus particle with an internal helical nucleocapsid-like structure and club 
shaped surface projections surrounding the periphery of the particle. The bars represent 100 




Figure 2. Typical Structure of Coronavirus Virion. (Source: Drazen et al., 2003) 
 
1.4 Molecular biology of SARS-CoV 
1.4.1 Genome organization 
The SARS-CoV genome is 29727 nt in length (excluding the 30 poly-A tail). Some 
isolates may have a 5’-end deletion up to 16 nt. The genome organization is similar to that of 
other coronaviruses. Fourteen open reading frames have been identified (Figure 3) (Thiel et al., 




Figure 3. SARS-CoV genome organization and expression. The putative functional ORFs in 
the genome of SARS-CoV are indicated.  The black box represents the 72-nt leader RNA 
sequence, derived from the 5’ end of the genome, located at the 5’ end of each viral mRNA. 
The 14 ORFs are expressed from the genome mRNA (mRNA 1) and a nested set of sub-
genomic RNAs (mRNAs 2–9). (Source: Thiel et al., 2003a) 
 
The two large 5’-terminal ORFs, 1a and 1b, which extend over two-thirds of the viral 
genome, encode for two huge polyproteins which are processed into 16 mature non-structural 
proteins, including proteases, RNA-dependent RNA polymerase, helicase, additional proteins 
necessary for viral RNA synthesis and other proteins with unknown functions. The remaining 
twelve ORFs encode the four structural proteins – spike protein (S), small membrane protein 
(E), membrane protein (M) and nucleocapsid protein (N), and eight additional non-structural 
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proteins with unknown functions. These non-structural proteins are not likely to be essential in 
tissue culture but may provide a selective advantage in the infected host (Thiel et al., 2003a).  
 
1.4.2 Viral RNA synthesis & translation 
Coronavirus RNA synthesis is carried out by the viral RNA-dependent RNA 
polymerase activity. Besides the full-length positive-sense genomic RNA, a nested set of 
positive-sense sub-genomic RNAs is also present in the infected cell (see Figure 3). 
Furthermore, for every positive-sense viral RNA, a complementary (negative-sense) RNA can 
also be found. 
As shown in Figure 3, each of the sub-genomic RNAs contains a short (50-100 nt) 
leader sequence from the 5’-end of the genome and a body sequence which is comprised of a 
characteristic length of sequence from the 3’-end of the genome (Thiel et al., 2003a). Early 
studies have clearly shown that the formation of sub-genomic RNAs is not done through the 
RNA splicing mechanisms commonly occurring in eukaryotes. Instead, various lines of 
evidence suggest that sub-genomic RNAs are generated by a unique polymerase “jumping” 
mechanism (reviewed in Lai & Holmes, 2001). This mechanism is dependent on cis-acting 
elements, known as ‘transcription-regulating signal’ (TRS), which include a stretch of a highly 
conserved core sequence(CS), 5’-ACGAAC-3’ for SARS-CoV or a highly related sequence for 
other coronaviruses. The TRS for each sub-genomic RNA encompasses genomic regions 
upstream of and at the 5’ end of the body sequence, although the exact boundaries of the TRS 
for any sub-genomic RNA have not been clearly defined. A TRS includes a CS of 6-7 nt, 
which is present at the 5’ end of the body sequence of each sub-genomic RNA as well as 3’-
end of the leader sequence. A TRS also includes a transcription attenuation signal which 
occurs upstream of the CS in the viral genome. The current most popular model of coronavirus 
sub-genomic RNA synthesis suggests that the polymerase switches template during the 
negative-sense RNA synthesis (Zuniga et al., 2004; Sawicki et al., 1998). Thus, after 
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synthesizing the sequence complementary to the CS in a TRS, the polymerase stalls as it 
encounters the attenuation signal. Then, through the base-pairing between the CS in the leader 
and the complementary CS in the nascent negative-sense RNA, and a series of protein–protein 
interactions in the transcription complex, the polymerase continues the negative-sense RNA 
synthesis using the leader RNA as the template (Zuniga et al., 2004). Thus, through continuous 
and discontinuous polymerization with the positive-sense genomic RNA as the template, all 
(genomic and various sub-genomic) negative sense-RNAs can be generated. The resulting 
negative-sense RNAs are in turn used as the templates to synthesize positive-sense genomic 
and sub-genomic RNAs. It is not known if the syntheses of genomic and sub-genomic, 
positive- and negative-sense RNAs use the same or different polymerase complexes. The 
presence in infected cells of all the sub-genomic RNAs as shown in Figure 3 has been 
confirmed experimentally (Thiel et al., 2003a).  
Coronavirus positive-sense genomic and sub-genomic RNAs are used as the templates 
for translation. On the genomic RNA, translation is initiated only at the 5’-most ORF 1a. ORF 
1a encodes a polypeptide of 4382 amino acid residues and is designated as polyprotein 1a 
(pp1a). In 25% to 30% of ORF 1a translation, ribosomal frameshifting into the –1 reading 
frame occurs just upstream of the stop codon, extending the translation into ORF 1b and thus 
yielding the 7073-residue polyprotein 1ab (pp1ab). The signals mediating the frameshift 
include a ‘slippery’ sequence, UUUAAAC, and a downstream RNA pseudo-knot structure 
(Thiel et al., 2003a). The sub-genomic RNAs 2, 4, 5 and 6 are functionally monocistronic in 
that only the 5’-most ORF on each RNA is translated. Sub-genomic RNAs 3, 7, 8 and 9, on the 
other hand, are functionally bicistronic in that two 5’-most ORFs can be translated (Figure 3) 
(Thiel et al., 2003a; Snijder et al., 2003).  
 
1.4.3 ORFs 1a and 1b 
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ORFs 1a and 1b encode two large polyproteins, pp1a (486 kDa) and pp1ab (790 kDa) 
(Thiel et al., 2003a). As described in Section 1.4.2, the expression of ORF 1b-encoded region 
of pp1ab involves ribosomal frameshifting into the −1 frame just upstream of the ORF 1a 
translation termination codon (Thiel et al., 2003a). 
The 5’-proximal region of ORF 1a of a typical coronavirus encodes two papain-like 
cysteine proteases, PL1pro and PL2pro. By contrast, SARS-CoV encodes only one papain-like 
protease. The activity of this protease has been demonstrated recently and it processes the N-
proximal region of pp1a at three sites (Thiel et al., 2003a). 
ORF 1a of SARS-CoV, like those of other coronaviruses, also encodes a 3C-like 
proteinase (3CLpro), which plays a critical role in coronavirus polyprotein processing. It 
produces the key replicative enzymes of the virus, such as RdRp and helicase. Therefore, it is 
also called the coronavirus main protease, Mpro (Ziebuhr et al., 2000; 2004). The activity of 
SARS-CoV 3CLpro has also been experimentally demonstrated (Fan et al., 2004; Hegyi et al., 
2002; Thiel et al., 2003a). It has a substrate specificity [(A,V,T,P)-X-(L,I,F,V,M)-
Q↓(S,A,G,N)] that is very similar to previously characterized coronavirus 3CLpros (Rota et al., 
2003; Gao et al., 2003a; Snijder et al., 2003; Thiel et al., 2003a). It cleaves pp1ab at all the 11 
predicted cleavage sites. The three-dimensional structure of 3CLpro was solved by both 
crystallography and NMR spectroscopy (Yang et al., 2003; Shi et al., 2004). Both studies 
reported that 3CLpro exists as a dimer and the conformational details of its interaction with 
substrates have been revealed, thus providing a basis for the anti-SARS drug design. As a 
result of the self-processing of pplab by the proteinase activities of PL2pro and 3CLpro, 16 
mature non-structural proteins (nsp) are produced (Figure 4) (Thiel et al., 2003a; Ziebuhr et al., 
2000; Anand et al., 2003).  
The 106-kDa SARS-CoV RdRp (nsp12) plays a pivotal role in viral RNA synthesis 
and is an attractive target for anti-SARS therapy. However, till now little is known about the 
structure and biochemical activity of any coronavirus RdRp. Recently, a structure model was 
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proposed for the catalytic domain of the SARS-CoV RdRp (Xu et al., 2003). The model gave a 
reasonable prediction about the active site of the protein and thus provided a useful platform 
for the rational design of effective inhibitors of this key enzyme. 
 
Figure 4. Overview of the domain organization and proteolytic processing of SARS-CoV 
replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa). The processing end-products of 
pp1a are designated nonstructural proteins (nsp) 1 to nsp11 and those of pp1ab are designated 
nsp1 to nsp10 and nsp12 to nsp16. Cleavage sites that are predicted to be processed by the 
viral main protease, 3CLpro, are indicated by grey arrowheads, and sites that are processed by 
the papain-like protease, PL2pro, are indicated by black arrowheads. TM stands for 
transmembrane domain; C/H stands for domain containing conserved Cys and His residues. 
(Source: Ziebuhr et al., 2004) 
 
Another important protein for viral replication is the SARS-CoV helicase (nsp13 in 
Snijder et al., 2003, or nsp10 in Gao et al., 2003a, and Tanner et al., 2003). The SARS-CoV 
helicase is a multifunctional protein. Its functions include: (i) single-stranded and double-
stranded RNA and DNA binding activities, (ii) nucleic acid-stimulated NTPase and dNTPase 
activities, (iii) RNA and DNA duplex unwinding activities, and (iv) RNA 5’-triphosphatase 
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activity, which is proposed to mediate the first step of 5’-cap synthesis on coronavirus RNAs 
(Tanner et al., 2003; Thiel et al., 2003a; Ivanov et al., 2004). 
SARS-CoV nsp9 can bind to RNA as well as another non-structural protein, nsp8 
(Sutton et al., 2004), but the importance of these activities is still unknown. Its crystal structure 
has been solved (Campanacci et al., 2003). It is deduced that the SARS-CoV nsp9 may have a 
similar function as the nsp9 protein of mouse hepatitis virus, a Group 2 coronavirus, which 
colocalized and interacted with other proteins of the replication complex (Bost et al., 2000; 
Brockway et al., 2003). For the remaining non-structural proteins produced from pp1a or 
pp1ab, possible functions have been predicted based on their functional domains or by their 
structural similarities to other proteins (Gao et al., 2003a; Snijder et al., 2003; Von Grotthuss et 
al., 2003). As many as five novel coronaviral RNA processing activities were predicted 
recently (Snijder et al., 2003). These include a 3’-to-5’ exonuclease (ExoN), an uridylate-
specific endoribonuclease (XendoU), a S-adenosylmethionine-dependent 2’-O-ribose 
methyltransferase (2’-O-MT), an ADP-ribose 1’’-phosphatase (ADRP), and a cyclic 
phosphodiesterase (CPD). Four of the activities are conserved in all coronaviruses, including 
SARS-CoV, suggesting their essential role in the coronaviral life cycle (Snijder et al., 2003). 
The fact that ExoN (nsp14), XendoU (nsp15) and 2’-O-MT (nsp16) are arranged in pp1ab as a 
single protein block downstream of the RdRp and helicase domains (Figure 4) suggests a 
cooperation of these activities in the same metabolic pathway (Snijder et al., 2003). The 
activities of the predicted coronavirus enzymes and their viral and/or cellular substrates still 
need to be revealed further. 
 
1.4.4 Structural proteins (S, E, M and N) 
Coronavirus S protein is a type I membrane glycoprotein, which is translated on 
membrane-bound polysomes, inserted into rough endoplasmic reticulum (RER), 
cotranslationally glycosylated, and transported to the Golgi complex. During the transport, S 
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protein is incorporated onto maturing virus particles, which assemble and bud into a 
compartment that lies between the RER and Golgi (Lai & Holmes, 2001). The S protein, which 
is thought to function as a trimer (Delmas et al., 1990), is important for binding to cellular 
receptor and for mediating the fusion of viral and host membranes and thus is critical for virus 
entry into host cells  (Collins et al., 1982; Godet et al., 1994; Kubo et al., 1993). S protein of 
SARS-CoV is 1255 amino acids long. It is predicted to have a 13 amino acid signal peptide at 
the amino-terminus, a single ectodomain (1182 amino acids) and a transmembrane region 
followed by a short cytoplasmic tail (28 residues) at the carboxy-terminus (Marra et al., 2003; 
Rota et al., 2003).  
Coronavirus S protein contains two regions with a 4, 3 hydrophobic (heptad) repeat 
(De Groot et al., 1987; Bosch et al., 2003). These domains (termed as HR1 and HR2) are 
thought to play an important role in defining the oligomeric structure of S and mediating the 
fusion between viral and cellular membranes (Eckert et al., 2001). For the SARS-CoV, HR2 is 
located close to the transmembrane anchor (1148–1193 amino acids) and HR1 is ~140 amino 
acids upstream of it (900–1005 amino acids) (Ingallinella et al., 2004). Biochemical studies 
have shown that peptides corresponding to the HR1 and HR2 of SARS- CoV S protein can 
associate into an anti-parallel six-helix bundles with structural features typical of class I fusion 
proteins. It is believed that SARS-CoV uses the same membrane fusion and cell entry 
mechanisms as other coronaviruses (Bosch et al., 2004; Ingallinella et al., 2004; Liu et al., 
2004; Tripet et al., 2004; Yuan et al., 2004; Zhu et al., 2004). 
Based on previous studies, S protein is an important target of virus-neutralizing 
antibodies (Chang et al., 2002; Collins et al., 1982; Fleming et al., 1983; Godet et al., 1994; 
Kant et al., 1992; Kubo et al., 1993, 1994; Takase-Yoden et al., 1991). It is reported that mice 
immunized with a recombinant S-protein, or a peptide derived from it, are protected from 
murine hepatitis virus (Daniel et al., 1990; Koo et al., 1999). 
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For SARS-CoV, a DNA vaccine encoding the S protein alone induced T cell and 
neutralizing antibody responses and protected mice from SARS-CoV infection (Yang et al., 
2004). It is quite possible that the S is the primary target for viral neutralization in SARS-CoV 
infection. This finding was also confirmed by several studies that use surrogate/carrier viruses 
to express S in mice or primates (Gao et al., 2003b; Bisht et al., 2004; Buchholz et al., 2004; 
Bukreyev et al., 2004). From these studies, it is clear that humoral response against S plays an 
important role in controlling and clearing SARS-CoV infection.  
SARS-CoV does not utilize any previously identified coronavirus receptors to infect 
cells and the cellular receptor for SARS-CoV has been identified to be angiotensin-converting 
enzyme 2 (ACE2) (Li et al., 2003a). Furthermore, syncytia formation/membrane fusion and 
viral replication can be specifically inhibited by an anti-ACE-2 antibody (Li et al., 2003a). But 
the molecular interactions between the S protein and ACE2 are not yet known.  
            Coronavirus E and M proteins are important for viral assembly. E protein is a small, 9–
12 kDa integral membrane protein (Siddell, 1995). The amino-terminus consists of a short 7–9 
amino acid hydrophilic region and a 21–29 amino acid hydrophobic region, followed by a 
hydrophilic carboxyl-terminal region (Shen et al., 2003). E protein also plays a part in viral 
morphogenesis. Co-expression of E and M proteins, from mouse hepatitis virus (MHV) (Bos et 
al., 1996; Vennema et al., 1996), transmittable gastroenteritis virus (TGEV), Bovine 
coronavirus (BCoV) (Baudoux et al., 1998), infectious bronchitis virus (IBV) (Corse et al., 
2000), and SARS-CoV (Ho et al., 2004) results in nucleocapsid independent formation of 
virus-like particles (VLPs). It is also reported that MHV and IBV E protein expressed alone 
results in assembly of E-protein-containing vesicles, with a density similar to that of VLPs 
(Corse et al., 2000; Maeda et al., 1999). The M glycoprotein is among the most abundant 
coronavius structural proteins, spanning the membrane bilayer three times, with a long 
carboxyl-terminal cytoplasmic domain inside the virion and a short amino-terminal domain 
outside (Holmes et al., 2001; Locker et al., 1992; Narayanan et al., 2000). By using a 
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proteomic approach, a novel phosphorylated site of M was also identified (Zeng et al., 2004), 
but the importance of this for the function of M has not been defined. Studies on the profile of 
antibodies in SARS patients showed that antibodies against M and E are generally low or not 
present in SARS patients’ sera (Wang et al., 2003; Guo et al., 2004; Leung et al., 2004; Tan et 
al., 2004). This is probably because these proteins are embedded in the viral envelope.  
The nucleocapsid protein N of SARS-CoV is a highly charged, basic protein of 422 
amino acids with seven successive hydrophobic residues near the middle of the protein (Marra 
et al., 2003; Rota et al., 2003). It undergoes self-dimerization (He et al., 2004; Surjit et al., 
2004a). It binds to viral RNA and the three-dimensional structure of its amino-terminal portion 
is similar to those of other RNA-binding proteins (Huang et al., 2004). It also interacts with M 
protein and cell membranes through its hydrophobic domain and may thus participate in viral 
assembly (Sturman et al., 1980). The N proteins of many coronaviruses, including IBV, TGEV 
and MHV, have been shown to localize in both cytoplasm and nucleolus (Hiscox et al., 2001; 
Wurm et al., 2001). The presence of N protein in the nucleolus suggests a role of N protein in 
the synthesis of viral RNA. In fact, it has been demonstrated that N protein is required for 
efficient coronavirus genome synthesis (Thiel et al., 2003b). However, it has also been shown 
that N protein is not required for sub-genomic RNA synthesis (Thiel et al., 2001). Therefore, 
the role played by N protein in viral RNA synthesis is still disputable. For SARS-CoV N 
protein, it has been reported to be found in the cytoplasm and nucleus of SARS-CoV infected 
cells (Chang et al., 2004; Zeng et al., 2004). Many effects of SARS-CoV N protein on cell 
function have been reported. It activates signal transduction pathways, interferes with cell-
cycle processes, induces apoptosis and reorganizes actin under stressed conditions (Parker et 
al., 1990; Kuo et al., 2002; He et al., 2003; Surjit et al., 2004b). It is cleaved by caspase 3 
(Ying et al., 2004). N proteins of many coronaviruses are highly immunogenic and expressed 
abundantly during infection (Liu et al., 2001; Narayanan et al., 2003). Several groups have 
shown that >90% of sera obtained from convalescent SARS patients have antibodies against N 
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(Shi et al., 2003; Wang et al., 2003; Guo et al., 2004; Leung et al., 2004; Tan et al., 2004). In 
addition, it was reported that the SARS-CoV N can induce specific T-cell responses (Gao et al., 
2003b; Kim et al., 2004), the same responses as have been observed with other coronaviruses 
(Siddell, 1995), but how important is this for protective immunity remains to be determined. 
 
1.5 Life cycle of coronavirus 
Coronavirus infection starts with the binding of the S protein on the surface of 
coronavirus binds to the receptor on the surface of human cell. Then, the nucleocapsid enters 
the cell through the fusion of the viral envelope with either the plasma membrane or 
endosomal membranes (Lai & Holmes, 2001). In the cytoplasm, uncoating proceeds through 
an unknown mechanism to release the viral RNA genome. The subsequent steps in coronavirus 
replication occur entirely in the cytoplasm of the host cells (Siddell et al., 1983). 
             Once released into the cytoplasm, the positive sense RNA genome is used as an 
mRNA for translation to produce the RNA-dependent RNA polymerase. The resulting 
polymerase uses the genomic RNA as the template to synthesize the negative sense genomic 
and sub-genomic RNAs. The negative sense RNAs in turn are used as the templates by the 
viral polymerase to synthesize new positive sense genomic and sub-genomic RNAs (Lai & 
Holmes, 2001). The newly synthesized positive sense RNAs will be used as mRNAs for 
translation to produce all viral structural and non-structural proteins. The N protein is 
synthesized by free ribosomes in the cytoplasm, while M, E and S protein are synthesized by 
the ribosomes on the rough endoplasmic reticulum (RER) and then transported into Golgi 
apparatus (Lai & Holmes, 2001). Assembly of new virions begins when substantial structural 
proteins have been synthesized. First, N protein binds to positive sense genomic RNA to form 
nucleocapsid. Then, through the interactions between N and M proteins and between M and S 
proteins, the virion is assembled in a compartment between RER and Golgi apparatus. The 
virion will undergo maturation as it is transported from Golgi apparatus to smooth-walled 
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vesicle along the secretory pathway and finally released as the vesicle fuses with the plasma 
membrane (Lai & Holmes, 2001). 
 
 
Figure 5. The life cycle of Coronavirus.  
 
1.6 Transmission of SARS-CoV 
The transmission pattern of SARS was similar in all affected areas. Normally, a patient 
with SARS was not identified when hospitalized and then infected health care workers, other 
patients and hospital visitors. These then infected their close contacts, and then the disease 































in droplets that are shed from the respiratory secretions of infected persons (Dwosh et al., 
2003). Although fecal or airborne transmission seem to be less frequent, faeces or animal 
vectors may also lead to transmission under certain circumstances (Ng et al., 2003). Shedding 
of SARS-CoV in urine also occurs but its outcome is unknown. The duration of infectivity is 
still unclear. Faecal shedding can last for several weeks; but no evidence showed that there is 
sufficient excretion of infectious viral particles to cause infection (Peiris et al., 2003a). It 
seems that SARS-CoV spreads more efficiently in hospital settings. Evidence suggests that 
certain procedures, such as intubation under difficult circumstances and the use of nebulizers, 
increase the risk of infection (Chan et al., 2003a).  A few cases of laboratory-acquired SARS-
CoV transmission were occurred in Singapore, Taiwan and China. Although subsequent 
investigation showed inappropriate laboratory standards and no secondary transmission arose 
from these cases, they demonstrate the need for appropriate biosafety precautions in 
laboratories working with SARS-CoV. These labs are the only places on earth where SARS-
CoV is currently known to still exist and might be at the source of re-emergence. The good 
news is that the SARS-CoV is only moderately transmissible rather than highly transmissible. 
A single infectious case will infect about three secondary cases (Lipsitch et al., 2003; Riley et 
al., 2003). Nevertheless, the clusters of cases in hotel and apartment buildings in Hong Kong 
show that transmission of the SARS-CoV can be extremely efficient and fast under certain 
circumstances. Attack rates in excess of 50% have been reported. In some instances, so-called 
"superspreader" patients are able to transmit the SARS-CoV to a large number of individuals 
(World Health Organization, 2003b). So far there is no evidence that differences in virus 
strains may be responsible for the “super-spreader” phenomenon. There is also no strong 
evidence suggesting that subsequent transmissions led clinically less severe illness, possibly 
through attenuation of the virus. It is also unclear why children are relatively under-represented 
amongst SARS cases, and why on average they seem to suffer less severe SARS illness. The 
virus has been shown to survive for up to hours on plastic surfaces and up to 4 days in stools. 
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Nevertheless the virus loses infectivity after exposure to some disinfectants and fixatives. Heat 
exposure at 56°C quickly reduces infectivity (World Health Organization, 2003c). In a word, 
SARS-CoV is not easily transmissible outside of certain environment. This suggests that 
SARS will not spread in a totally uncontrolled manner in the community. 
 
1.7 Epidemiology of SARS 
The SARS coronavirus is believed to originate from Guangdong province of southern 
China (Breiman et al., 2003). The worldwide spread of SARS-CoV was triggered by a single 
infected teacher from Guangdong province who spent some time in Hong Kong before he died 
because of SARS (Chan et al., 2003b). During that time he infected several others that in turn 
caused a series of outbreaks (Centers for Disease Control and Prevention, 2003). During a few 
months, the virus spread to different Hong Kong hospitals and communities as well as to 
Vietnam, Singapore, Canada, the United States of America, and beyond to a total of 30 
countries and areas of the world (World Health Organization, 2003d).  
The incubation period of SARS ranges from 2 to 16 days. Large studies demonstrated 
a median incubation period of 6 days (Booth et al., 2003; Lee et al., 2003; Tsang et al., 2003). 
However, the time from exposure to the onset of symptoms may vary considerably (Donnelly 
et al., 2003). The WHO recommends that the current best estimate of the maximum incubation 
period is 10 days (WHO Update 49, 2003). Based on the latest data, the case fatality ratio is 
estimated to be <1% in persons aged 24 years or younger, 6% in persons aged 25–44 years, 
15% in persons aged 45–64 years, and greater than 50% in persons aged 65 years and older 
(Donnelly et al., 2003; WHO Update 49, 2003). It seems that, compared with adults and 
teenagers, younger children can resist SARS-CoV more efficiently (Hon et al., 2003). At the 
present time, with no new cases having been reported since 15 June 2003 (except from the 
isolated laboratory-acquired one), SARS-CoV has apparently been driven out of the human 
population (World Health Organization, 2003d). But even now, where this new virus was from 
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and how it started to infect humans remains a mystery. Researchers from the University of 
Hong Kong examined 25 animals belonging to seven wild and one domestic animal species in 
a live animal market in southern China that supplies restaurants in Guangdong province. Some 
of these animals were tested positive for SARS-like virus (Guan et al., 2003). However, the 
results didn’t conclude whether any one (or more) of these animals is the natural reservoir in 
the wild. It is possible that these animals were all infected from another unknown animal 
source (possibly a smaller mammal easily consumed by them), which is possibly the true 
reservoir in nature (Guan et al., 2003). Further extensive investigation would be helpful to 
understand the animal reservoir and the interspecies transmission events that led to the 
outbreak of SARS. 
 
1.8 Diagnosis of SARS 
As defined by the WHO, a person is suspected to have SARS if he/she has 
documented high fever (>38°C), plus cough or breathing difficulty, and has been in contact 
with a person believed to have had SARS, or has a history of travel to or stay in a geographic 
area where documented transmission of the illness has occurred, during the 10 days prior to 
onset of symptoms (“suspect case”). A suspect case with infiltrates consistent with pneumonia 
or respiratory distress syndrome (RDS) by chest X-ray is reclassified as a probable case. The 
revised case definition as of 1 May 2003 (http://www.who.int/csr/sars/casedefinition/en/) 
includes virus-specific laboratory results: a suspect case that tests positive for SARS-CoV in 
one or more assays should also be reclassified as probable. The latest WHO case definitions 
are summarized in Table 1. 
While recommendations have been issued for the use of laboratory methods for SARS-
CoV identification (http://www.who.int/csr/sars/labmethods/en/), there are, however, at present 
no defined criteria for negative SARS-CoV test results to reject a diagnosis of SARS. Given 
the facts that virus excretion is comparatively low during the initial phase of SARS (Drosten et  
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Table 1. World Health Organization case definitions of SARS patients. (Source: 
http://www.who.int/csr/sars/postoutbreak/en/) 
Clinical case definition of SARS                 A person with a history of: 
                                                                       Fever (≥ 38°C) 
                                                                       AND one or more symptoms of lower respiratory tract 
                                                                       illness (cough, difficulty breathing, shortness of breath) 
                                                                       AND radiographic evidence of lung infiltrates consistent 
                                                                       with pneumonia or RDS  
                                                                       OR autopsy findings consistent with the pathology of 
                                                                       pneumonia  
                                                                       OR RDS without an identifiable cause. 
                                                                       AND No alternative diagnosis can fully explain the illness. 
 
Laboratory case definition of SARS          A person with symptoms and signs that are clinically 
                                                                       suggestive of SARS 
                                                                       AND with positive laboratory findings for SARS-CoV 
                                                                       based on one or more of the following diagnostic criteria: 
                                                                       a) PCR positive for SARS-CoV 
                                                                           PCR positive using a validated method from: 
                                                                           At least two different clinical specimens (eg 
                                                                           nasopharyngeal and stool)   
                                                                           OR the same clinical specimen collected on two or more 
                                                                           occasions during the course of the illness (eg sequential 
                                                                           nasopharyngeal aspirates)  
                                                                           OR Two different assays or repeat PCR using a new 
                                                                           RNA extract from the original clinical sample on each  
                                                                           occasion of testing.  
                                                                       b) Seroconversion by ELISA or IFA 
                                                                           Negative antibody test on acute serum followed by 
                                                                           positive antibody test on convalescent phase serum  
                                                                           tested in parallel  
                                                                           OR fourfold or greater rise in antibody titre between  
                                                                           acute and convalescent phase sera tested in parallel. 
                                                                       c) Virus isolation 
                                                                           Isolation in cell culture of SARS-CoV from any  
                                                                           specimen  
                                                                           AND PCR confirmation using a validated method 
*ELISA = enzyme-linked immunosorbent assay; IFA = immunofluorescence assay;                               
RDS = respiratory distress syndrome. 
 
al., 2003), and the insufficient sensitivity of presently available laboratory methods, premature 
exclusion on the basis of negative test results may lead to tragic consequences. Positive 
laboratory test results for other agents able to cause atypical pneumonia may serve as exclusion 
criteria; according to the case definition, a case should be excluded if an alternative diagnosis 
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can fully explain the illness. Nevertheless, the possibility of dual infection must not be ruled 
out completely (http://www.who.int/csr/sars/sampling/en/). 
 
1.9 Pathogenesis of SARS-CoV 
The fatal pneumonia caused by SARS-CoV has the following distinct features 
(Nicholls et al., 2003): 
    • epithelial cell proliferation 
    • diffuse alveolar damage 
    • macrophage infiltration of the lungs 
    • haemophagocytosis (a feature attributed to cytokine dysregulation). 
These pathological features of SARS-CoV pneumonia are similar to H5N1 influenza 
pneumonia (To et al., 2001). Experimental studies in which macrophages are infected in vitro 
suggest that the H5N1 influenza viruses are hyper-inducers of pro-inflammatory Cytokines 
(Cheung et al., 2002). Human coronavirus can replicate in human macrophages in vitro (Li et 
al., 2003b; Collins et al., 1998). Based on these knowledge, it has been suggested that, in 
SARS-CoV pneumonia, pro-inflammatory cytokines released by stimulated macrophages in 
the alveoli have a prominent role in the pathogenesis of SARS leading to cytokine 
dysregulation. This idea has applications for the management of coronaviral pneumonia, as 
interventions with steroids might modulate this cytokine response and prevent fatal outcome 
(Collins et al., 1998). 
 
1.10 Antiviral treatment 
At present, an efficacious treatment regimen for SARS is still unavailable. Primary 
methods include isolation and the implementation of stringent infection control measures to 
effectively prevent further transmissions. When making the treatment choices, the severity of 
the illness is a major factor to be considered. Ribavirin and steroids are the drugs which were 
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administered most frequently over the first months of the epidemic. The combination was 
initially thought to be responsible for some clinical improvement in SARS patients (Lee et al., 
2003; Poutanen et al., 2003; Tsang et al., 2003). 
Recently glycyrrhizin, a compound found in liquorice roots (Glycyrrhiza glabra), was 
reported to have in vitro anti-SARS activity (Cinatl et al., 2003a). Furthermore, interferons 
inhibit SARS-CoV in vitro and interferon ß was more potent than interferon α or γ (Cinatl et 
al., 2003b). Therefore, it could be a promising candidate against SARS-CoV, alone or in 
combination with other antiviral drugs. 
Many research institutions around the world have been working on finding the 
potential anti-SARS agents in vitro. Based on previous studies, some steps unique to SARS-
CoV could be targeted for the development of antiviral drugs. Possible antiviral drugs (Holmes 
et al., 2003a) are: 
• Inhibitors of the SARS virus entry and membrane fusion: They could block the binding of the 
S protein on the viral envelope to a specific receptor on the cell membrane or inhibit receptor- 
induced conformational change in the S protein on the viral envelope; 
• Protease inhibitors: They could inhibit the cleavage of the large polyprotein encoded by the 
ORF 1a and b; 
• Inhibitors of SARS-CoV RNA synthesis (such as nucleoside analogs): They might interfere 
specifically with SARS-CoV replication without damaging the cell; 
• Assembly inhibitors: They could prevent coronavirus structural proteins and newly 
synthesized RNA genomes from assembling into new virions. 
 
1.11 Viral Replicon, anti-viral drug screening and the aim of this project 
The causative agent of SARS has been identified to be a novel coronavirus. Although 
the initial SARS outbreak has been over, the likelihood of human and animal reservoirs 
suggest that this virus will continue to pose a worldwide public health threat. To better control 
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or prevent future SARS epidemics, anti-SARS vaccines and drugs need to be developed. To 
maximize the chance of finding efficacious anti-SARS drugs, high-throughput screening of 
large chemical libraries for compounds that can block SARS-CoV replication should be carried 
out. However, the high infectivity and virulence of SARS-CoV render this kind of research 
very dangerous. Therefore, there is a need for an anti-viral agent identification system which 
does not involve the use of live virus. For all families of human-infecting positive-sense 
single-stranded RNA viruses, partial viral RNA genomes have been constructed such that they 
replicate and persist in dividing cells without producing viral particles (Kaplan et al., 1988; 
Liljestrom et al., 1991; Khromykh et al., 1997; Behrens et al., 1998; Lohmann et al., 1999; 
Pang et al., 2001; Shi et al., 2002; Thumfart et al., 2002; Hertzig et al., 2004). These viral 
replicons were derived from viral genomes through the deletion of all or some structural genes. 
Because of the absence of viral structural genes, virion proteins were not synthesized in the 
cells and therefore no infectious viral particle could be produced by the cells. However, since 
all trans- and cis-acting components required for viral RNA synthesis were retained, these 
partial viral RNAs could replicate autonomously in the cells. In fact, hepatitis C virus replicon-
carrying cell lines have been widely used to identify specific antiviral agents (Carroll et al., 
2003; Kapadia et al., 2003). With these positive precedents, it seemed likely that a replicon cell 
line could be developed for SARS-CoV and such a cell line would be a much safer system for 
anti-SARS drug screening. The development of a SARS-CoV replicon cell line was the very 
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2.1 Design of SARS-CoV replicon 
The SARS-CoV genome and the desired replicon derived from it are shown in Figure 
6 top and bottom respectively. As shown, the viral envelope-protein coding genes S, E and M 
were excluded from the replicon so as to disable virion synthesis. The nucleocapsid gene, N, 
was retained because the nucleocapsid protein had been shown to be required for viral RNA 
synthesis (Almazan et al., 2004; Hertzig et al., 2004). It was shown that the sequence involved 
in the regulation of expression of a coronavirus 3’-proximal gene includes more than 100 nt 
upstream of the gene (Alonso et al., 2002; Jeong et al., 1996). Therefore, in order to achieve 
relatively native expression of N gene from the replicon, a region of ~300 nt upstream of N 
ORF was included in the replicon. This region actually encompassed the non-structural ORFs 
8a and 8b of SARS-CoV and the transcription regulatory core sequence for mRNA 8 (Figure 
3). The green fluorescent protein-blasticidin deaminase fusion (GFP-BlaR) gene was included 
into the replicon to enable easy selection and detection of replicon-containing cells. It was 
inserted between ORFs 1 and 8-N, not at the 5’ or 3’ end of the replicon, in order to minimize 
any possible deleterious effect on the synthesis of replicon RNA. It was known that the cis-
acting elements for efficient coronavirus genome replication occur at both the 5’ and 3’ ends of 
the genome covering parts of ORFs 1 and N (Lai & Holmes, 2001). The expression of GFP-
BlaR was driven by the transcription regulatory sequence of ORF S, which was included in the 
replicon and occurring at a position right upstream of the GFP-BlaR gene. 
 
2.2 Construction of SARS-CoV replicon 
2.2.1 Overview of replicon construction strategy 
The reverse genetic strategy for constructing the desired SARS-CoV replicon is 
illustrated in Figure 6. In brief, cDNAs for the SARS-CoV genomic regions to be included in 
the replicon were first generated from the virus genomic RNA by RT-PCR. GFP-BlaR gene 















Figure 6. SARS-CoV replicon and the strategy for its construction. Each SARS-CoV 
sequence-containing DNA intermediates is identified with a name, and its virus-derived 
regions are delimited by the genomic coordinates SARS-CoV strain SIN2774. The 5’-caps and 
3’-polyadenine tails of the SARS-CoV genome and replicon RNAs are omitted. Gb stands for 
green fluorescent protein-blasticidin deaminase fusion gene, L stands for leader sequence. 
 
plasmid pTracer™-CMV/Bsd (Invitrogen). The SARS-CoV cDNAs and GFP-BlaR gene DNA 
were then cleaved by restriction endonucleases and assembled together through ligation to 
form the SARS-CoV replicon transcription template. Finally, this template was transcribed in 
vitro to generate the desired SARS-CoV replicon RNA. 
As shown in Figure 6 and described in Section 2.1, the desired SARS-CoV replicon 
consisted of the GFP-BlaR gene sandwiched between two SARS-CoV regions: the 5’ region 
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size (21 kb), the 5’ region had to be separated into a few sub-regions in cDNA synthesis. 
Therefore, the desired replicon had to be assembled from multiple DNA fragments. Yount et al. 
(2000) have devised an elegant approach to assemble multiple DNA fragments in vitro. This 
approach uses restriction endocleases recognizing specific DNA sequences but cleaving DNA 
at nearby sites with no specific sequence requirement (non-palindromic restriction 
endocleases). Such enzymes are used to prepare DNA fragments to be assembled in such a 
way that each end of each fragment is complementary only to one end of another specific DNA 
fragment. As such, multiple DNA fragments can then be assembled in the desired order in one 
simple ligation in vitro. We adopted this approach to construct our SARS-CoV replicon 
transcription template. 
Two major difficulties were encountered in the generation of our SARS-CoV replicon 
transcription template. First, even though in principle a lot of DNA fragments can be 
assembled orderly all at once using the aforementioned approach, the efficiency of getting the 
desired full-length assembly product decreases as the number of fragments to be assembled 
increases. Therefore, the initial number of DNA fragments has to be minimized. However, for 
most non-palindromic restriction endonucleases, the SARS-CoV genetic sequences to be 
included into the replicon contain too many recognition sites. No restriction endonuclease 
could be used singly to prepare all the cDNAs for the assembly of the entire replicon. 
Therefore, combinations of different restriction endonucleases were tried. The second major 
difficulty was in the cDNA amplification by PCR. Certain regions of SARS-CoV genome were 
particularly difficult to amplify efficiently and/or faithfully. Very small amounts of products or 
aberrant products (mostly having internal deletions) were obtained when certain priming sites 
and thermophilic DNA polymerase preparations were used in the PCRs. Therefore, many 
different priming sites and DNA polymerase preparations were tried. 
After extensive optimization of individual reactions, a satisfactory strategy for the 
assembly of SARS-CoV replicon transcription template was developed (Figure 6). In this 
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strategy, the SARS-CoV 5’ region was amplified into three cDNAs (designated as A, B, and 
C). The non-palindromic restriction endonuclease Bsa I was used in the assembly of B, C, Gb 
(GFP-BlaR gene-containing) and N (SARS-CoV 3’ region-containing) cDNAs. The Bsa I 
recognition site at the junction between B and C is endogenous of SARS-CoV genomic 
sequence. Other Bsa I recognition sites were introduced into the cDNAs from the PCR primers. 
The Bsa I-cleaved B, C, Gb and N cDNAs were first assembled to form the BCGbN DNA. 
Finally, the BCGbN DNA and A cDNA were ligated together at the restriction endonuclease 
PshA I recognition site endogenous of SARS-CoV genome to generate the ABCGbN DNA. 
ABCGbN DNA contains a primer-introduced T7 transcription promoter upstream to 
the replicon sequence. It could thus be used as the template for the synthesis of the 
replicon RNA through T7 RNA polymerase-mediated in vitro transcription. 
 
 31
Notes for Sections 2.2.2-2.4.5: In these sections, reactions were described with reference to 
certain volumes. However, different reaction volumes could actually be used according to the 
needs. In such cases, the actual amounts or volumes of individual reaction components used 
were changed proportionally. All the primers used were synthesized by Research Biolab 
Singapore Pte Ltd and their sequences are listed in Appendix 1. 
 
2.2.2 Synthesis of SARS-CoV first-strand cDNA by reverse transcription  
SARS-CoV strain SIN2774 virion RNA (a gift of Prof. T. K. Chow, Department of 
Microbiology, National University of Singapore) was used as the template for cDNA synthesis. 
The reverse transcription reaction was performed using the SuperScript III First Strand Kit 
(Invitrogen) as described in the manufacturer’s manual with some modifications. Thus, the 
following components were first added to an RNase-free microcentrifuge tube: 
      Gene-specific primer 9R or 09R (10 µM)                       0.5 µl 
      SARS-CoV virion RNA (unknown concentration)         1.0 µl 
      dNTP Mix (10 mM each)                                                1.0 µl 
      RNAase-free water                                                          7.5 µl 
The reaction mix was heated to 65°C for 5 minutes and chilled on ice for at least 1 
minute. The tube was then spun briefly and the following components were thoroughly mixed 
in: 
      10X First-Strand Buffer                                              2 µl 
      MgCl2 (25 mM)                                                          4 µl 
      DTT (0.1 M)                                                               2 µl 
      RNaseOUT (40 units/µl)                                             1 µl 
      SuperScript III RT (200 units/µl)                                1 µl 
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The reaction mix was incubated at 50°C for 2 hours followed by heating at 85℃ for 5 
minutes and chilling on ice. One microliter of E. coli RNase H was then added and incubated 
at 37°C for 20 minutes. The reaction mix was chilled on ice and stored in -20℃ until use.  
  
2.2.3 Synthesis of A DNA 
The TripleMaster PCR System (Eppendorf) was used to synthesize the SARS-CoV 
sequence-containing A DNA. The PCR was performed as described in the manufacturer’s 
manual with certain modifications. Thus, two master mixes with the following components 
were first prepared on ice: 
      Master Mix 1                                                                 20 µl 
      Molecular biology grade water                                       15 µl 
      Forward primer T71+F (10 µM)                                       2 µl 
      Reverse primer 09R (10 µM)                                            2 µl 
      SARS-CoV first-strand cDNA from Section 2.2.1           1 µl 
      Master Mix 2                                                                  30 µl 
      Molecular biology grade water                                    22.1 µl 
      10x Tuning Buffer with Mg2+                                        5.0 µl 
      dNTP mix (10 mM each)                                               2.5 µl 
      TripleMaster Polymerase Mix (5 units/µl)                    0.4 µl 
Master Mixes 1 and 2 were then mixed together on ice in a 0.2 ml PCR tube, which 
was immediately placed into a GeneAmp® 9700 thermal cycler (Applied Biosystems) pre-
heated at 93°C. It was followed by the running of the thermal cycling program as detailed in 
Table 2.  
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Table 2. Thermal cycling program optimized for the amplification of SARS-CoV cDNA 
fragment A. 
Cycle no  Cycle Step Temp. Time Description 
  1 93 1 min Initial template denaturation 
2 93 10 sec Template denaturation 





4 68 9 min Primer extension/elongation 
5 93 10 sec Template denaturation 





7 68 9min+20sec* Primer extension/elongation 
*Time increment of 20 seconds; for each elongation step the time was extended by 20 seconds 
 
2.2.4 Synthesis of B, C and N, and GFP-BlaR gene DNAs 
The SARS-CoV sequence-containing B, C and N DNAs were synthesized by PCR 
using the Elongase Amplification System (Invitrogen). For the synthesis of each DNA, a 50-µl 
reaction was set up by mixing on ice the following components: 
      Molecular biology grade water                                        35 µl 
      Forward primer (see below) (10 µM)                                1 µl 
      Reverse primer (see below) (10 µM)                                1 µl 
      SARS-CoV first-strand cDNA from Section 2.2.1           1 µl 
      5X Buffer A                                                                      4 µl 
      5X Buffer B                                                                       6 µl 
      dNTP mix (10 mM each)                                                  1 µl 
      Elongase Enzyme Mix                                                      1 µl 
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The reaction tubes were immediately placed into GeneAmp® 9700 thermal cycler pre-
heated at 94°C. After incubation at 94℃ for 30 seconds, the following cycling program was 
started: 35 cycles with each cycle consisting of 94℃ for 30 seconds, 55℃ for 30 seconds, and 
68℃ for 2 to 5 minutes (~1 minute per kb of target fragment). Finally, the reaction mixes were 
heated to 72℃ for 10 minutes, cooled to 4℃ and then stored at -20℃. The gene-specific 
primers used were 09F and 11R for the amplification of B, 12F and 14R2 for C, NFX and 9R 
for N. 
The GFP-BlaR gene DNA was amplified as described above, except that the template 
was pTracer™-CMV/Bsd vector DNA (1 ng) and the primers were BGBF and BGBR.  
 
2.2.5 Assembly and amplification of BCGbN DNA 
The B, C, N and GFP-BlaR gene DNAs were first purified using the QIAquick PCR 
Purification Kit (Qiagen) as described in the manufacturer’s manual. The purified DNAs were 
then digested with restriction endonuclease Bsa I (New England Biolabs). Each 50-µl reaction 
was composed on ice with 20 µl of purified DNA (~100 ng/µl), 2 µl of Bsa I (10 units/µl), 5 µl 
of 10 × NEBuffer 3 and 23 µl of molecular biology grade water. The reaction mixes were 
incubated at 50°C for 2 hours. The restriction products were then electrophoresced on 0.8% 
agarose gels in TBE. The gel portions containing the desired DNAs were excised. The DNAs 
were then extracted from the gel slices using the QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions.  
To assemble the BCGbN DNA, the Bsa I-digested and gel purified B, C, N, and GFP-
BlaR gene DNAs were ligated together using T4 DNA ligase (New England Biolabs). A 50-µl 
ligation reaction was composed on ice with 10 µl of each of the four DNAs (~100 ng/µl), 2 µl 
of T4 DNA Ligase (400 cohesive end units/µl), 5 µl of 10 x T4 DNA Ligase Reaction Buffer 
and 3 µl of molecular biology grade water. The ligation was carried out at 16°C for 14 hours. 
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The ligation product was then electrophoresced on a 0.5% agarose gel in TBE. The gel 
portion containing the desired BCGbN DNA was excised. The DNA was extracted from the 
gel using the QIAquick Gel Extraction Kit according to the manufacturer’s instructions. 
Due to the inefficiency of multiple DNA ligation, the yield of full-length BCGbN 
DNA was very low. Therefore, it was necessary to amplify BCGbN DNA to produce sufficient 
quantities for the downstream reactions. The Elongase Amplification System was used to 
achieve this purpose. To set up a 50-µl reaction, the following components were mixed on ice:  
      Molecular biology grade water                                        35 µl 
      Forward primer 6F (10 µM)                                              1 µl 
      Reverse primer 9R (10 µM)                                               1 µl 
      Gel-purified first-round BCGbN DNA (~2 ng/µl)            1 µl 
      5X Buffer A                                                                       4 µl 
      5X Buffer B                                                                       6 µl 
      dNTP mix (10 mM each)                                                   1 µl 
      Elongase Enzyme Mix                                                      1 µl 
The reaction mix was immediately placed into GeneAmp® 9700 thermal cycler pre-











Table 3. Thermal cycling program optimized for the amplification of BCGbN DNA.  
Cycle no  Cycle Step Temp. Time Description 
 1 1 94 20 sec Initial template denaturation 
2 94 5 sec Template denaturation 





4 68 13 min Primer extension/elongation 
5 94 10 sec Template denaturation  
6-35 
 
30× 6 68 13min+20sec* Primer annealing/extension 
*Time increment of 20 seconds; for each elongation step the time was extended by 20 seconds 
 
2.2.6 Assembly of ABCGbN DNA 
The SARS-CoV sequence-containing A and BCGbN DNAs were first purified using 
the QIAquick PCR Purification Kit according to the manufacturer’s instructions. They were 
then digested with restriction endonuclease PshA I (New England Biolabs). A 50-µl reaction 
was composed on ice with 42.5µl of A or BCGbN DNA (~200 ng/µl), 2µl of PshA I (10 
units/µl), 5 µl of 10 × NEBuffer 4 and 0.5 µl of BSA (10 µg/µl). The reaction mixes were 
incubated at 37°C for 3 hours. The restriction products were then electrophoresced on a 0.5% 
agarose gel in TBE. The gel portions containing the desired DNAs were excised. The DNAs 
were then extracted from the gel slices using the QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions. 
To assemble the ABCGbN DNA, the PshA I-digested and gel purified A and BCGbN 
DNAs were ligated using T4 DNA ligase. A 100-µl ligation reaction was composed on ice 
with 43 µl of each DNA (~60 ng/µl), 4 µl of T4 DNA Ligase (400 cohesive end units/µl), 10 µl 
of 10 x T4 DNA Ligase Reaction Buffer. The ligation was carried out at 12°C for 14 hours. 
The resulting DNA was extracted first by phenol-chloroform-isoamyl alcohol (25:24:1), then 
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by chloroform, and precipitated in the presence of 67% ethanol and 0.1 M sodium acetate 
(pH5.2). Shortly before the performance of in vitro transcription (see below), the extracted 
DNA was pelleted by centrifugation, washed with 70% ethanol, air-dried and finally dissolved 
in 10 µl of RNase-free water. 
 
2.2.7 Synthesis of SARS-CoV replicon RNA 
The assembled ABCGbN DNA contained a primer-introduced T7 transcription 
promoter. It could thus be used as the template for the synthesis of SARS-CoV replicon RNA 
through T7 RNA polymerase-mediated in vitro transcription. The T7 in vitro transcription 
system mMessage mMachine Kit (Ambion), which also includes the RNA 5’-capping function, 
was used to generate the replicon RNA. A 30-µl reaction mix was composed on ice with 2.5 µl 
of RNase-free water, 15 µl of 2 × NTP/CAP, 3 µl of 10× Reaction Buffer, 2 µl of ABCGbN 
DNA preparation from Section 2.2.6 (~0.5 µg/µl), 4.5 µl of GTP (30 mM) and 3 µl of Enzyme 
Mix. The reaction mix was incubated at 37°C for 2 hours.  To remove the DNA template, 1 µl 
of DNase I (2 units/µl) was then added and the reaction mix was incubated at 37°C for 15 
minutes. To polyadenylate the RNA synthesized, the reaction mixture was treated further by 
the reagents from the Poly (A) Tailing Kit (Ambion). Thus, 26 µl of RNase-free water, 20 µl 
of 5 × E-PAP Buffer, 10 µl of MnCl2 (5 mM), 10 µl of ATP (10 mM) and 4 µl of E –PAP were 
added in the given order. The reaction mix was incubated further at 37°C for 1 hour. The final 
product was purified by adding 30 µl of LiCl precipitation solution (Ambion) and incubating at 
–20°C for 30 minutes, followed by centrifugation at maximum speed for 15 minutes at 4°C to 
pellet the RNA. The RNA was washed once with 1 ml of 70% ethanol, air-dried, and finally 




2.3 Development of SARS-CoV replicon-carrying cell lines 
 The baby hamster kidney (BHK)-21 cell line was purchased from ATCC. It was used 
to develop the SARS-CoV replicon-carrying cell lines as described below. 
 
2.3.1 Maintenance of BHK-21 Cell Line 
BHK-21 cell line was maintained in 5 ml of DMEM medium (Gibco) supplemented 
with 10% foetal calf serum (Gibco) (D10) in 25-cm² tissue culture flasks at 37°C in a 
humidified CO2 tissue culture incubator (Jouan). Whenever confluence was reached, the cells 
were detached from the flask by first washing with 5 ml of PBS and then incubating in 0.5 ml 
of 0.05% trypsin solution (Gibco). When the majority of cells were detached, the flask was 
tapped gently to complete the cell detachment. Then, 4.5 ml of D10 was added to stop 
trypsinization and the cell suspension was pipetted up and down a few times to maximize the 
separation of cells from each other. A 0.5-ml aliquot of cell suspension was transferred into a 
new flask. Finally, 4.5 ml of fresh D10 was added to the flask before the cells were put into the 
tissue culture incubator for further growth. 
 
 2.3.2 Transfection of BHK-21 cells with SARS-CoV replicon RNA 
On the day before the transfection was to be carried out, BHK-21 cells were plated 
onto a 6-well plate using D10 (2 ml/well) such that the cells would be 40-50% confluent the 
next day. For the transfection of cells in one well, 10 µl of the transfection agent 
Lipofectamine 2000 (Invitrogen) was first diluted into 250 µl of Opti-MEM medium 
(Invitrogen) in a 1.5-ml eppendorf tube. In a separate tube, 10 µl (~10 µg) of SARS-CoV 
replicon RNA preparation from Section 2.2.7 was diluted into 250 µl of Opti-MEM medium. 
Both tubes were left at room temperature for 5 minutes. The contents of the two tubes were 
then mixed together and left at room temperature for 20 minutes to allow the formation of 
RNA-Lipofectamine 2000 complex. During this time, the original D10 was removed from the 
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cells to be transfected and replaced with Opti-MEM medium (0.5 ml/well) after a PBS wash of 
the cells. Then, the RNA-Lipofectamine complex preparation (0.5 ml /well) was added into the 
cells. The treated cells were incubated in the tissue culture incubator for 4-6 hours. Finally, 
DMEM medium supplemented with 20% fetal calf serum (1 ml/well) was added to the treated 
cells and the cells were incubated further in a tissue culture incubator. 
 
2.3.3 Selection for and continuous culturing of SARS-CoV replicon-carrying cells  
The SARS-CoV replicon contained the GFP-BlaR gene under the control of the viral 
transcription regulatory sequence. The cells carrying the replicon should express the GFP-BlaR 
gene and therefore be resistant to blasticidin. Accordingly, one day after tranfection, blasticidin 
(Invitrogen) was added to a final concentration of 10 µg /ml to the culture medium to select for 
the replicon-carrying cells. Two days after the introduction of blasticidin, the transfected cells 
were distributed into several wells in 6-well plates and incubated further in D10 with 10 µg/ml 
of blasticidin (D10B). The blasticidin-sensitive cells died and detached from the growth 
surface within one week. They were removed together with the culture medium. After two 
PBS washes, fresh D10B was added to the wells and the blasticidin-resistant cells were 
allowed to grown further. Blasticidin-resistant cell colonies appeared in two weeks. Several 
colonies with diameters over 1 mm were isolated and grew further in the presence of 
blasticidin in separate 25-cm² tissue culture flasks. The isolates that continued to grow were 
designated as BHK-SCR cell lines. They were maintained using the same procedure as 
described in Section 2.3.1 for maintaining the parent BHK-21 cells, except that D10B was 
used. 
Although the SARS-CoV replicon-carrying cells do not produce infectious viral 
particles, they are still associated with some biological risks. If a replicon-carrying cell is 
infected by a circulating field coronavirus, there is a chance of producing a novel replication-
competent recombinant coronavirus through the recombination between the SARS-CoV 
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replicon and the genome of the circulating field coronavirus. The pathogenicity of such a 
recombinant coronavirus cannot be assessed. In view of this risk, a special standard operating 
procedure (SOP) for handling the SARS-CoV replicon cell line was set up by my thesis 
supervisor Dr. Hung Siu Chun. This SOP was approved by the Institutional Biosafety 
Committee of our University with the acknowledgement of notification from the Genetic 
Modification Advisory Committee, Singapore. The fundamental principle behind this SOP is 
to take utmost care to prevent the cross-contamination between the replicon cell line and the 
environment. Accordingly, the replicon cell line is basically handled using BSL2 facilities and 
BSL2 work practices. Additional precautions include, first, the decontamination in the earliest 
possible instant inside the BSL2 cabinet of any surface having come into contact with the 
replicon cell culture, including the inner surface of a pipette, and, second, the use of double 
containers to carry the replicon cell culture outside of the BSL2 cabinet with their outer 
surfaces decontaminated before being taken out of the BSL2 cabinet. The SOP was strictly 
followed throughout the course of this work. 
 
2.4 Analysis of SARS-CoV replicon-carrying BHK-21 cell line 
 Two blasticidin-resistant cell lines generated as described in Section 2.3.3 were 
designated as BHK-SCR1 and BHK-SCR2 and subjected to analyses pertinent to the SARS-
CoV replicon that they carried. The parent cell line BHK-21 was used as the negative control 
in these analyses. 
 
2.4.1 Detection of GFP-BlaR protein  
Fluorescence microscopy and flow cytometry were used to observe the green 
fluorescence of GFP-BlaR protein expressed from the SARS-CoV replicon. They were done at 
various time points to monitor the presence of the replicon in the cells. 
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2.4.1.1 Fluorescence microscopy 
The cells to be observed were grown to near confluence on a 6-well plate. They were 
first washed once with PBS and then fixed with 4% formaldehyde in PBS for 15 minutes and 
finally washed twice with PBS. The treated cells were observed under an Olympus IX70 
inverted fluorescence microscope. The images were recorded using Image-Pro Plus (Media 
Cybernetics).  
 
2.4.1.2 Flow cytometry 
The cells were first detached from the growth surface by trypsinization as described in 
Section 2.3.1 and then transferred to a 15-ml centrifuge tube. They were pelleted by 
centrifugation at 300×g for 5 minutes, rinsed once with PBS, fixed with 4% formaldehyde in 
PBS, washed twice with PBS and finally resuspended in PBS at a cell density of about 106 per 
ml. The cells were then scanned for green fluorescence and light scattering using a Beckman 
Coulter Epics Altra flow cytometer. The data collected were analyzed using the WIN-MDI 2.7 
data analysis program (The Scripps Research Institute).  
 
2.4.2 Detection of SARS-CoV replicon and sub-replicon RNAs by Northern blot analysis 
In the cells carrying the SARS-CoV replicon, coronavirus-specific discontinuous 
transcription (Section 1.4.2) should take place on the replicon leading to the production of sub-
replicon RNAs, L-Gb-8-N, L-8-N and L-N, as depicted in Figure 7. Northern blot analysis was 
carried out to detect for these SARS-CoV replicon and sub-replicon RNAs extracted from the 

















Figure 7. Generation of sub-replicon RNAs through discontinuous transcription of SARS-CoV 
replicon RNA in the replicon-carrying cells. The black box represents the 72-nt leader RNA 
sequence, derived from the 5’ end of the replicon, located at the 5’ end of each sub-replicon 
RNA. The size of each RNA shown is exclusive of the poly-A tail. 
 
2.4.2.1 Probe preparation  
The Gene Images Random Prime Labeling Module (Amersham) was used to prepare  
fluorescein-labelled probes. Since SARS-CoV N gene sequence should be found in all replicon 
and sub-replicon RNAs (Figure 7), this sequence was the target for detection. Accordingly, the 
template for probe preparation was the 2-kb SARS-CoV N DNA (Figure 6), which was 
synthesized and gel-purified as described in Sections 2.2.4 and 2.2.5 respectively. It was 
denatured by heating for 5 minutes in a boiling water bath and was rapidly chilled on ice. A   
50 µl labeling reaction was set up on ice with 31 µl of nuclease-free water, 10 µl of labeled 
nucleotide mix, 5 µl of random nonamer primer mix, 3 µl (~50 ng) of denatured SARS-CoV N 




SCR replicon cell 












37°C for 1 hour. The reaction was then terminated by the addition of EDTA to a final 
concentration of 20 mM. The probe preparation was stored at -20°C until use. 
 
2.4.2.2 Preparation of RNA  
To extract total RNA from SARS-CoV replicon-carrying cells or the parent BHK-21 
cells, about 4 × 106 cells were first detached from the growth surface by trypsinization as 
described in Section 2.3.1. They were transferred to a 15-ml centrifuge tube and pelleted by 
centrifugation at 300 × g for 5 minutes. After the removal of the supernatant, the cell pellet was 
then subjected to RNA extraction using the RNeasy Mini Kit (QIAGEN) according to the 
Animal Cell Protocol supplied by the manufacturer.  
A SARS-CoV N sequence-containing RNA was used as a positive control for the 
detection of SARS-CoV replicon and sub-replicon RNAs. To generate this RNA, SARS-CoV 
N DNA, which was synthesized and gel-purified as described in Sections 2.2.4 and 2.2.5 
respectively, was first inserted into the vector pCR2.1-TOPO (Invitrogen), which has a T7 
promoter at one side of the cloning site. A clone was selected with the insert in the orientation 
such that T7-transcription of which would produce RNA containing the direct SARS-CoV N 
sequence. DNA from this clone was linearized at a vector location at the side opposite to the 
T7 promoter with respect to the SARS-CoV N insert. One-microgram of this linear DNA was 
used as the template for in vitro transcription using the mMessage mMachine Kit performed 
according to the manufacturer’s instructions. The 2150-nt SARS-CoV N sequence-containing 
RNA thus synthesized was used as the positive control. 
 
2.4.2.3 Electrophoresis and capillary-transfer of RNA 
                The RNAs were electrophoresed under denaturing conditions. They were first 
denatured by mixing individually with 9 volumes of denaturing sample buffer (see Appendix 2) 
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followed by heating at 85°C for 5 minutes. RNA electrophoresis was carried out using a gel 
with 0.8% agarose, 1 × MOPS (see Appendix 2) and 6.6% formaldehyde, and a buffer 
containing 1 × MOPS and 6.6% formaldehyde. It continued until the bromophenol blue sample 
dye nearly reached the far end of the gel. The gel was then washed in 10 volumes of water for 
15 minutes. The RNAs in the gel were partially cleaved by soaking the gel in 5 volumes of 
alkaline solution (see Appendix 2) at room temperature for 30 minutes with gentle agitation. 
Afterwards, the gel was washed once in 5 volumes of neutralization solution (see Appendix 2) 
and twice in 5 volumes of 10 × SSC, each for 30 minutes. A capillary transfer apparatus was 
then assembled as shown in Figure 8 to transfer the RNAs from the gel onto a Hybond-N+ 
positively charged nylon membrane (Ambion). The capillary transfer was allowed to proceed 
for 20-24 hours. Finally, the RNAs were fixed onto the nylon membrane by UV irradiation 
using an automatic UV cross-linker (Vilber Lourmat). 
 
2.4.2.4 Probe hybridization and signal generation 
The hybridization of probes to the immobilized RNAs on the nylon membrane and the 
subsequent signal generation were done using the reagents from the Gene Images CDP-Star 
Detection Module (Amersham). The nylon membrane with immobilized RNAs (blot) was first 
pre-hybridized in the hybridization buffer (see Appendix 2) for 2-4 hours at 65° in a  
hybridization incubator (FinePCR) in the way that there was a constant, even and slow flow of 
hybridization buffer over the blot surface. One-fifth milliliter of hybridization buffer was used 
per cm² of blot. For hybridization, 1.5 µl of probes (prepared as described in Section 2.4.2.1) 
was used per ml of hybridization buffer. The appropriate volume of probes was first diluted 
with RNase-free water to 20 µl and then denatured by boiling for 5 minutes. The denatured 
probes were then carefully mixed into the buffer for pre-hybridizing the blot. The hybridization 













Figure 8. The capillary transfer apparatus 
 
those used in pre-hybridization. After hybridization, the blot was washed twice in the low 
stringency wash buffer (1 × SSC, 0.1% SDS) and then twice in the high stringency wash buffer 
(0.1 × SSC, 0.1 % SDS). Each wash was done at 65°C for 15 minutes using 1.25 ml of buffer 
per cm² of blot. Following the stringency washes, the blot was incubated in blocking buffer 
(see Appendix 2; 1 ml per cm² of blot) and then in anti-fluorescein-AP conjugate solution (see 
Appendix 2; 0.3 ml per cm² of blot), each for 1 hour at room temperature with gentle agitation. 
Afterwards, the blot was washed thrice with AP wash buffer (see Appendix 2; 5 ml per cm² of 
blot), each for 10 minutes, at room temperature. After draining off excess wash buffer from the 
blot, CDP-Star detection reagent was added evenly onto the blot at 30-40 µl per cm² of blot. 
After incubation at room temperature for five minutes, excess detection reagent was drained 
off and the blot was sealed inside a clean transparent plastic bag. Chemiluminescent signals 
emitted from the blot were detected by exposing a Hyperfilm-MP X-ray film (Amersham) to 
the blot for various durations between 1 to 30 minutes, followed by the photographic 















2.4.3 Analysis of SARS-CoV sub-replicon RNAs by RT-PCR 
As depicted in Figure 7, sub-replicon RNAs having the 5’-proximal leader joined to 
3’-proximal genes should be produced in the SARS-CoV replicon-carrying cells. The region of 
a sub-replicon RNA encompassing the junction between the 5’-proximal leader and 3’-
proximal gene (leader-body junction) can be amplified by RT-PCR using a forward primer 
specific to the leader and a reverse primer specific to the 3’-proximal gene. Besides providing 
evidence for the specific discontinuous transcription, this RT-PCR also produces a product 
which can be sequenced to locate the leader-body junction precisely. 
To amplify the leader-body junction of the L-Gb-8-N or L-N sub-replicon RNA 
(Figure 7), total RNA was first extracted from SARS-CoV replicon-carrying cells as described 
in Section 2.4.2.2. Two micrograms of total RNA was used as the template for RT-PCR, which 
was performed using the OneStep RT-PCR Kit (QIAGEN). Besides the RNA template, the    
50 µl reaction also contained 1 × QIAGEN OneStep RT-PCR buffer, 400µM of each dNTP, 
0.6 µM of each of the forward and reverse primers, 2.0 µl QIAGEN OneStep RT-PCR Enzyme 
Mix and 10 units of RNase inhibitor. The leader-specific forward primer was SCVLF. The 
reverse primers for the amplification of L-Gb-8-N and L-N sub-replicon RNAs were 
GFPBLAR and NR respectively.  
 The reaction mix was placed into a GeneAmp® 9700 thermal cycler. It was first 
maintained at 50°C for 30 minutes for reverse transcription to take place. Afterwards, it was 
heated to 95°C for 15 minutes to inactivate the reverse transcriptase as well as to activate the 
HotStar DNA polymerase in the Enzyme Mix. This was followed by 35 thermal cycles, each 
consisting of three steps: first, 94℃ for 40 seconds; second, 55℃ for 40 seconds; and third, 
72℃ for 20 or 30 seconds for the detection of L-Gb-8-N or L-N sub-replicon RNA 
respectively. Finally, the reaction mixes were maintained at 72℃ for 10 minutes and then 
cooled to 4℃. 
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2.4.4 Detection of GFP-BlaR gene in total cell DNA 
GFP-BlaR gene DNA was not expected to occur in the SARS-CoV replicon-carrying 
cells. The following procedures were done to confirm its absence. 
 
2.4.4.1 Extraction of total cell DNA 
To extract total DNA from SARS-CoV replicon-carrying cells or the parent BHK-21 
cells, about 4 × 106 cells were first detached from the growth surface by trypsinization as 
described in Section 2.3.1. They were transferred to a 15-ml centrifuge tube and pelleted by 
centrifugation at 300 × g for 5 minutes. After the removal of the supernatant, the cell pellet was 
then subjected to DNA extraction using the QIAamp DNA Mini Kit (QIAGEN) according to 
the Protocol for Cultured Cells supplied by the manufacturer.  
 
2.4.4.2 PCRs for the detection of GFP-BlaR and GAPDH genes 
PCRs were performed using HotStarTaq DNA polymerase (Qiagen) and the 
accompanying reagents. Each 30-µl PCR was composed on ice such that it contained ~0.2 µg 
of total cell DNA prepared as described in Section 2.4.4.1, 1 × PCR buffer, 200 µM of each 
dNTP, 0.2 µM of each primer and 0.75 units of HotStarTaq DNA polymerase. The primers 
used for detecting GFP-BlaR gene were BGBF and BGBR, and those for detecting GAPDH 
gene were GAPDHF and GAPDHR. The reaction mix was placed into GeneAmp® 9700 
thermal cycler pre-heated at 95°C. After incubating at 95℃ for 15 minutes to activate the 
polymerase, 35 thermal cycles were run with each cycle consisting of 94℃ for 45 seconds,    
55℃ for 5 seconds, and 72℃ for 70 seconds for amplifying GFP-BlaR gene or 30 seconds for 
amplifying GAPDH gene. Finally, the reaction mix was maintained at 72℃ for 10 minutes and 
then cooled to 4℃. The GFP-BlaR and GAPDH PCR products were expected to be 1.2 kb and 
0.45 kb in size respectively. 
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2.4.5 Sequencing of SARS-CoV replicon and sub-replicon RNAs 
To obtain the complete sequence of the SARS-CoV replicon persisting in the BHK-
SCR2 cells, total RNA was extracted from these cells using the same method as described in 
2.4.2.2. A set of 13 overlapping SARS-CoV replicon cDNAs of about 2 kb in size 
encompassing the entire replicon was generated from the total RNA as described in 2.4.3, 
except that the duration of the third step in each thermal cycle was 2.5 minutes and that the 
primers used were shown in Table 4. The cDNAs were purified using QIAquick Purification 
Kit according to the manufacturer’s instruction and then subjected to DNA sequencing using 
Big Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Each sequencing 
reaction mix was composed on ice with 4 µl of 2.5 × Big Dye Terminator Ready Reaction Mix, 
2 µl of 5 × sequencing buffer, 50 ng of purified cDNA and 3.2 µl of 1 µM sequencing primer, 
topped up to 20 µl with molecular biology grade water. The sequencing reactions were 
performed in a GeneAmp® 2400 Thermal Cycler. The thermal cycle program used and the 
subsequent purification and drying of the sequencing reaction products were done according to 
the instructions from the manufacturer of the cycle sequencing kit. The purified products were 
sent to the NUS Microbiology Department DNA Sequencing Facility for electrophoresis and 
sequence read-out using an ABI PRISM 3100 Genetic Analyser (Applied Biosystems). The 
sequencing data thus obtained were compared with the published sequence of SARS-CoV 
strain SIN2774 (GenBank Accession Number AY283798) using the MegAlign module of the 
sequence analysis software Lasergene (DNASTAR). Thirty-nine sequencing reactions were 
first done aiming to cover the entire SARS-CoV replicon. Regions with ambiguities, apparent 
base changes, or gaps were then re-sequenced with the same or new primers until the sequence 
of the entire replicon could be read with confidence. Altogether 47 sequencing primers were 
employed. They are listed in Table 4. 
To locate the leader-body junction in the leader-GFP-BlaR-N or leader-N sub-replicon 
RNAs, the cDNA obtained from each sub-replicon RNA as described in Section 2.4.3 was 
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subjected to the same cycle sequencing analysis as described above with GFPBLAR or NR as 
the sequencing primer respectively. 
 
Table 4. SARS-CoV Replicon sequencing strategy 
RT-PCR 
Products 
RT-PCR Primers  Sequencing Primers*   
1 T71+F, 2R T71+F3, 1R, 2R  
2 3F, SP4251R 3R, 02R, SAP1R2, SP4251R 
3 04F, A1R 04F, 4F 
4 4FX, SAR1R 4FX, SP6081F, SAP1R 
5 06F, 06R 06F, SCVD555RP, 06R, SAP2F 
6 5F, 4RX 5F, 07F, 4RX 
7 5FX, SAP2R 5FX, SCVD3709RP, SAP2R, 08R 
8 6F, 10R 6F, SP12918F, SP13639F, 09R, 10F, 10R  
9 SP13639F, 11R SP15762R, 6R, 11R 
10 12F, 12R 12f, SP16769f, 12R 
11 SP17970F, 13R SP17970F, SP18680F, 13F,13R 
12 SP19400F, 14R2 SP19400F, 8F, 14F  
13 BBIBlF, 16R2 BBIBlF, NFX, SP28384F, 16R2, NR 



















3.1 Generation of SARS-CoV replicon RNA 
  The goal of this thesis project was to develop a SARS-CoV replicon-carrying cell line. 
To achieve this goal, the viral replicon RNA had to be generated first. The design of the viral 
replicon has been described in Section 2.1. The strategy for the construction of the replicon has 
been described in Section 2.2.1 and illustrated in Figure 6. Following this strategy, the initial 
task to accomplish was to assemble the replicon transcription template DNA, ABCGbN. To 
this end, the B, C and N cDNAs were first generated from the SARS-CoV virion RNA using 
RT-PCR and Gb DNA was amplified from the plasmid pTracer™-CMV/Bsd using PCR as 
described in Section 2.2.4. They are shown in Figure 9A lanes 2 to 4. To obtain the assembly 
intermediate BCGbN DNA, B, C, N and Gb DNAs were digested by the restriction 
endonuclease Bsa I, gel-purified and ligated together. The result is shown in Figure 9A lane 5. 
A ligation product with the size close to that expected of BCGbN (12.6 kb) was obtained, but 
in a small amount. The multi-component ligation was apparently inefficient. One possible 
contributing factor to the inefficiency of this ligation could be the incomplete Bsa I digestion 
of the reactant DNAs. Being primer-introduced, most Bsa I recognition sites were occurring 
very close to the ends of the reactant DNAs. The direct confirmation of digestion at such sites 
is very tedious and therefore was not done. Even though the Bsa I digestion of the reactant 
DNAs was carried out for a time much longer than that required to completely digest internal 
Bsa I sites, the digestion close to the DNA ends could be less efficient and therefore be 
incomplete. Since the BCGbN DNA obtainable directly from the multicomponent ligation was 
too small in amount to be used for further DNA assembly, it was amplified to a much larger 
amount using PCR as described in Section 2.2.5. The result is shown in Figure 9B lane 2. 
The other component for the assembly of the replicon transcription template was the 
13-kb SARS-CoV A cDNA. It was synthesized using RT-PCR as described in Section 2.2.3. 


















Figure 9. Generation of SARS-CoV replicon transcription template DNA. (A) Multi-
component ligation for the assembly of BCGbN DNA. The DNAs to be ligated (B, C, Gb and 
N) and the ligation products (BCGbN Ligation) are as indicated. The white arrow indicates the 
assembled BCGbN DNA (lane 5). A 1-kb DNA ladder (Promega) is shown on lane 1, and the 
sizes of selected marker bands are indicated on the left. (B) The assembly of ABCGbN DNA. 
The DNAs to be ligated (A and BCGbN) and the ligation products (ABCGbN Ligation) are as 
indicated. The arrow indicates the assembled ABCGbN DNA. A λ phage DNA Hind III-digest 
is shown on lane 4, and the sizes of selected fragments are indicated on the right. The DNAs 
shown in panels A and B were electrophoresed on 0.8% and 0.5% agarose gels in TBE 
respectively, stained with 0.5 µg/ml of EtBr and visualized by irradiation with ultraviolet light 






































































































To obtain the complete replicon transcription template DNA ABCGbN, A and BCGbN 
DNAs were digested with the blunt-end-generating restriction endonuclease PshA I, gel-
purified, and ligated together. The result is shown in Figure 9B (lane 3). A ligation product 
with the size expected of ABCGbN (25.6 kb) was obtained, although in a small amount. The 
inefficiency of this ligation could be due to the fact that it was a blunt-end ligation. Also 
because of the fact that this was a blunt-end ligation, the desired ABCGbN was not the only 
ligation product. The undesired A dimers and BCGbN dimers should also be generated through, 
respectively, the self-ligation of two A DNA molecules at the downstream ends and self-
ligation of two BCGbN DNA molecules at the B-proximal ends. In the PshA I digestion, only 
the downstream end of A and the B-proximal end of BCGbN were digested, whereas the other 
two ends, i.e. the upstream end of A and the N-proximal end of CDGbN, were not. The latter 
two ends should have 3’-protruding adenosines because they were generated by PCRs using 
polymerase mixes that contained relatively high levels of non-proof-reading polymerases. 
Because of this, these two ends should not be involved in ligation and thus other undesired 
dimers or higher-order ligation products should not be generated. 
For an in vitro transcription to be successful, the DNA template has to be free from 
imperfection. If the DNA template has undergone degradative changes, such as nicking and 
thymidine dimer formation, the transcription on this template will not be able to proceed over 
the entire length. A large piece of DNA, such as ABCGbN (25.6 kb), is very liable to undergo 
such degradative changes when it is subjected to manipulations, such as ultraviolet irradiation, 
centrifugation, and vortexing. Therefore, attempt was not made to remove the unligated DNAs 
and undesired ligation products from ABCGbN DNA. The total DNA from the above ligation 
reaction, after an extraction using phenol-chloroform, was used directly as the template in the 
in vitro transcription for the synthesis of SARS-CoV replicon RNA as described in Section 
2.2.7. For a rough quality inspection, an aliquot of the post-transcription mixture was analyzed 
on a regular (non-denaturing) agarose gel. The result is shown in Figure 10 lane 2. As shown, a 
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Figure 10. Generation of SARS-CoV replicon RNA.  The products of in vitro transcription for 
the generation of the replicon RNA is shown on lane 2. Lane 1 shows a λ phage DNA EcoR I 
and Hind III-digest with the sizes of selected fragments indicated on the left. These nucleic 
acids were electrophoresed on a 0.5% agarose gels in TBE, stained with 0.5 µg/ml of EtBr and 
visualized by irradiation with ultraviolet light of 300 nm. 
 
large amount of high molecular weight nucleic acid was observed, which formed an intense 
slow migrating smear on the gel. Since the post-transcription mixture was treated with DNase I 
and the nucleic acid observed did not have the same electrophoretic mobilities as the input 
DNA (Figure 9B lane 3), the nucleic acid observed should be the product of transcription – 
RNA. RNase digestion could be used to confirm the identity of the nucleic acid. It was not 
used because of the fear of apparatus contamination. The smeary appearance of the RNA could 










reaction, which added variable numbers of adenosine nucleotides to different RNA molecules. 
The RNA molecules observed should thus indeed have variable sizes. Second, the RNA 
molecules might form alternative secondary structures with different mobilities on the gel. 
Although this non-denaturing agarose gel analysis could not show precisely the sizes of the 
RNA products, it was good enough to show that the RNA products are in a molecular weight 
range high enough to include the full-length SARS-CoV replicon RNA. Therefore, these RNA 
products should be good enough to be used to transfect BHK-21 cells for the generation of the 
desired SARS-CoV replicon cell line. It was expected that only a very small percentage of 
these RNA products could be full-length functionally active SARS-CoV replicon RNA. The 
main reason was that the reverse-transcription and PCRs for the generation of the transcription 
template and the in vitro transcription for the generation of SARS-CoV replicon RNA were 
relatively error-prone, and therefore only a very low percentage of replicon RNA would not be 
inactivated by the base substitutions acquired during these processes. Another reason was the 
presence of significant amount of unwanted DNA in the transcription template preparation as 
described above. 
 
3.2 Generation and analysis of SARS-CoV replicon-carrying cells 
 To generate SARS-CoV replicon-carrying cells, the in vitro transcription products 
obtained as described in Section 3.1 was first purified by LiCl precipitation as described in 
Section 2.2.7 and then used to transfect BHK-21 cells as described in Section 2.3.2. Because of 
the expectedly low percentage of functionally active replicon RNA, the percentage of cells 
acquiring functionally active replicon RNA was also expected to be very low. Therefore, the 
transfected cells were not analyzed for the presence of the replicon immediately. Instead, the 
transfected cells were first subjected to blasticidin selection as described in Section 2.3.3 to 
enrich for the replicon-carrying cells. The expression of GFP-BlaR gene from the replicon 
would render the replicon-carrying cells resistant to blasticidin. After 5 days of blasticidin 
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treatment, a lot of cells had died. Transfected cells in some wells were processed for 
fluorescence microscopic observation as described in Section 2.4.1.1. In these wells, clusters 
of green-fluorescent cells could be found. A typical green-fluorescent cell cluster is shown in 
Figure 11A. As shown, the morphology of the green-fluorescent cells was typical of BHK-21 
cells. There was no sign for any cytotoxicity of the SARS-CoV replicon.  
The transfected cultures were maintained further under blasticidin selection in order to 
obtain the cells that carried the SARS-CoV replicon consistently. After two weeks of 
blasticidin selection, practically all non-resistant cells had died and been removed, leaving 
behind colonies of blasticidin-resistant cells in the wells. A few blasticidin-resistant 
 
 
Figure 11. Green fluorescence from BHK-21 cells transfected by SARS-CoV replicon RNA. 
(A) Combined green fluorescence and phase-contrast microscopic images of a portion of 
transfected cell culture after five days of blasticidin treatment, showing a cluster of green-
fluorescent cells among non-fluorescent cells. (B) Green fluorescence images of the cells 
expanded from a blasticidin-resistant cell colony isolated after two weeks of selection and 
passaged under selection for one additional week. 
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colonies emerged in each of the two transfections done. Several colonies were isolated and 
expanded in the presence of blasticidin. After one further week of growth, a portion of cells 
from each colony was examined using fluorescence microscopy. Figure 11B shows the images 
of cells expanded from one such colony. As can be seen, almost all the cells were fluorescing 
in green with similar intensities. Thus, it was likely that they were originated from one cell 
transfected with functional SARS-CoV replicon RNA. The same observation was obtained 
from and therefore the same conclusion could be drawn for each of the other colonies (data not 
shown). In Figure 11B, a lot of cells appeared to round up. This was due to the fact that the 
cells were left in PBS for a prolonged period of time before they were processed for 
fluorescence microscopy. In culture, they actually showed the typical morphology of BHK-21 
cells (data not shown). 
When the green fluorescence intensities of the cells from different colonies were 
compared, however, obvious differences could be noticed (data not shown). This could be due 
to the possibility that different original transfected cells had acquired different copy numbers 
of functional replicon RNA and thus produced different amounts of GFP-BlaR protein. Two 
isolates with the highest levels of green fluorescence were selected for further analyses and 
they were designed BHK-SCR1 and BHK-SCR2 cell lines.  
The blasticidin resistant and green fluorescent cell lines were first tested for the 
absence of GFP-BlaR gene DNA. In the in vitro transcription for the synthesis of SARS-CoV 
replicon RNA, the transcription product was treated with DNase I to remove the template 
DNA (Section 2.2.7). Despite that, there could still be DNA contamination in the replicon 
RNA preparation. Should GFP-BlaR gene DNA be present in the RNA preparation, it could 
entered cells through transfection, integrated into cell chromosomes and was expressed from 
the integration sites. This would render the cells blasticidin resistant and green fluorescent, just 
as if they were carrying the replicon RNA. Therefore, to exclude this possibility, the absence 
















Figure 12. Absence of GFP-BlaR gene DNA in SARS-CoV replicon-carrying cells. As 
indicated, PCR was carried out to amplify GFP-BlaR or GAPDH gene DNA using GFP-BlaR 
sequence-containing plasmid DNA (pGFPblaR), BHK-SCR1 (SCR1) or BHK-SCR2 (SCR2) 
cells as the template. A 100-bp DNA ladder (Promega) is shown on lane 1, and the sizes of 
selected marker bands are indicated on the left. These DNAs were electrophoresed on a 1% 
agarose gels in TBE, stained with 0.5 µg/ml of EtBr and visualized by irradiation with 
ultraviolet light of 300 nm. 
 
confirmed. Accordingly, total DNA was isolated from BHK-SCR1 and BHK-SCR2 cells as 
described in Section 2.4.4.1 after four weeks of growth under blasticidin selection and detected 
for GFP-BlaR gene DNA using PCR as described in Section 2.4.4.2. As shown in Figure 12 

































































if the lack of product in these reactions was due to inappropriate reaction conditions, a PCR 
was performed simultaneously using the same reagents except that 1 ng of plasmid DNA 
containing the GFP-BlaR sequence was used as the template. As shown in Figure 12 lane 2, a 
large amount of product of the expected size was obtained. This showed that the PCR 
conditions were appropriate. To check if the degradation of total DNA or the presence of PCR 
inhibitors in the total DNA preparations was the cause of the failure to amplify GFP-BlaR 
sequence, these total DNA preparations were used as the templates to amplify the 
housekeeping gene GAPDH as described in Section 2.4.4.2. As shown in Figure 12 lanes 5 and 
6, PCR products of the expected size could be obtained from these DNA preparations, thus 
ruling out the existence of such problems in the total DNA preparations. Taken together, these 
PCR results confirmed the absence of GFP-BlaR gene DNA in BHK-SCR1 and BHK-SCR2 
cells. Therefore, the most probable explanation for the blasticidin-resistance and green 
fluorescence of these cells was the expression of GFP-BlaR protein from the SARS-CoV 
replicon in these cells. This would imply that the replicon RNA had persisted in the cells for 
three weeks. BHK-SCR1 and -SCR2 cells underwent cell division once every 20 hours. 
Therefore, they had divided for more than 25 times and their numbers had increased more than 
30 million folds in three weeks. The persistence of SARS-CoV replicon in these cells for this 
duration underlines the capability of the replicon to replicate in these cells.  
 Next, the presence of the SARS-CoV replicon in BHK-SCR1 and -SCR2 cells was 
studied directly by the use of Northern blot analysis. Thus, total RNA was isolated from these 
cells after four weeks of growth under blasticidin selection and then analyzed as described in 
Section 2.4.2. The SARS-CoV replicon, if functional, should undergo coronavirus-specific 
discontinuous transcription inside the cells and lead to the production of three sub-replicon 
RNAs, namely L-Gb-8-N, L-8-N and L-N, as depicted in Figure 7. The results of the Northern 
















Figure 13. Presence of SARS-CoV replicon and sub-replicon RNAs in replicon-carrying cells 
at detected by northern blot analysis. Total RNA preparations from BHK-21 (BHK), BHK-
SCR1 (SCR1) and BHK-SCR2 (SCR2) cells, and an RNA containing SARS-CoV N gene 
sequence generated in vitro as described in Section 2.4.2.2 (N RNA) were analyzed as 
indicated. Each total RNA preparation was analyzed in two amounts, 10µg and 1µg, as 
indicated. Images from two durations of blot exposure, 15 minutes (long expo) and 1 minute 
(short expo), are shown. The positions of 28S and 18S rRNAs from the total cell RNA 
preparation, noted from the gel after electrophoresis and EtBr-staining, are indicated on the 
right. The bands corresponding to the replicon and the expected sub-replicon RNAs (L-Gb-8-N, 
L-8-N & L-N), are identified based on their electrophoretic mobility relative to those of N 
RNA, 28S and 18S rRNAs. The bands corresponding to unexpected sub-replicon RNAs, 
































































RNAs could be identified from the blot. In cells infected by SARS-CoV or any other 
coronaviruses, the sub-genomic RNA for N gene translation is much more abundant than the 
genomic RNA (Thiel et al., 2003a). Accordingly, in the SARS-CoV replicon-carrying cells,  
the abundance of the sub-replicon RNA for N gene translation (L-N) was much higher than 
that of the replicon RNA (Figure 13). The abundance of the sub-replicon RNA for GFP-BlaR 
gene translation (L-Gb-8-N) was higher than that of the replicon RNA but much lower than 
that of L-N (Figure 13). This intermediate abundance of L-Gb-8-N was also expected because 
the production of L-Gb-8-N was controlled by the transcription regulatory signal for the 
production of SARS-CoV S gene-translating sub-genomic RNA, and it was known that, in 
SARS-CoV-infected cells, the abundance of this sub-genomic RNA is intermediate between 
that of the genomic RNA and that of the N gene-translating sub-genomic RNA (Thiel et al., 
2003a). The abundance of the sub-replicon RNA for ORF 8 translation (L-8-N), however, was 
unexpected high, even higher than that of L-N (Figure 13). In SARS-CoV-infected cells, the 
sub-genomic RNA for ORF 8 translation is much lower than that of the sub-genomic RNA for 
N gene translation (Thiel et al., 2003a). The reason for this unexpectedly high abundance of L-
8-N was not known at this point. It was shown that the abundance of a sub-genomic RNA 
could be affected by the genomic sequence more than 100-nt upstream of the body sequence of 
the sub-genomic RNA (Alonso et al., 2002; Jeong et al., 1996). In the SARS-CoV replicon, the 
GFP-BlaR gene sequence was inserted at about 50-nt upstream of the transcription regulatory 
core sequence for ORF 8. Therefore, it was likely that a part of GFP-BlaR gene sequence 
somehow enhanced the abundance of L-8-N. Two additional sub-replicon RNAs with sizes 
larger than that of L-Gb-8-N could be observed on long exposure to the blot (Figure 13, 
indicated by asterisks). They were of very low levels and unknown origin. Overall, this 
Northern blot analysis showed that the SARS-CoV replicon and sub-replicon RNAs were 
present in the cells four weeks after the initial introduction of the replicon RNA into the cells. 
During this period of time, the cells had divided for more than 33 times. Thus, it was clear that 
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the SARS-CoV replicon could replicate efficiently in the cells and it did not show negative 
effect on cell growth. Together with the data presented above showing the absence of GFP-
BlaR DNA in these replicon-carrying cells, it can be concluded that the blasticidin-resistance 
and green fluorescence of these cells were caused by the presence of the replicon in these cells. 
 The SARS-CoV replicon RNA was initially generated from the virus genomic RNA 
through reverse transcription, repeated PCRs, followed by in vitro transcription using T7 RNA 
polymerase. All these reactions are quite error-prone. The viral sequences included in the 
replicon were very large – altogether about 23.5 kb. Therefore, it was likely that most of the 
replicon RNA molecules generated in this way carried some base alterations from the wild-
type virus genomic RNA. During the intracellular propagation of the replicon, base alterations 
that are inhibitory to replicon RNA replication should be selected against. On the other hand, it 
is possible that some base alterations from the wild-type viral sequence enable better 
adaptation to persistent RNA replication in growing cells and they are selected for. Therefore, 
the sequence of the replicon obtained after prolonged intracellular propagation could reveal 
base alterations that are permissible for or promoting replicon RNA replication and persistence. 
To obtain the sequence of the persistent SARS-CoV replicon, overlapping cDNAs 
encompassing the entire replicon were generated from the total RNA of BHK-SCR2 cells after 
one month of cell growth and their sequences were obtained as described in Section 2.4.5. The 
sequences thus obtained were compared with the wild-type SARS-CoV SIN2774 strain 
sequence. It was found that the persistent replicon contained no base alteration from the wild-
type virus sequence (data not shown). Since most of the replicon RNA molecules initially 
introduced into the cells were expected to contain base alterations whereas base alteration was 
absent from the persisting replicon, it is likely that all the wild-type viral sequences included in 
the replicon are essential for replicon RNA replication and persistence. However, since it has 
not been directly shown that the replicon RNA initially introduced into the cells actually 
carried base alterations, firm conclusion cannot be drawn.  
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The essential sub-replicon RNAs, L-Gb-8-N and L-N, that are translated to produce 
GFP-BlaR and N proteins respectively, were shown to be present in the BHK-SCR1 and -
SCR2 cells using Northern blot analysis as described above. They were identified based on 
their electrophoretic mobilities relative to those of RNAs with known sizes. Another way to 
show the presence of a SARS-CoV sub-replicon RNA is to detect for the joint between the 
viral 5’-leader and the corresponding body gene in the sub-replicon RNA. Thus, to show the 
presence of L-Gb-8-N and L-N in BHK-SCR12 cells using this approach, RT-PCRs were first 
performed as described in Section 2.4.3 to obtain the cDNAs containing the corresponding 
leader-body joints. As shown in Figure 14, these cDNAs were amplified from the total RNA of 
BHK-SCR2 cells but not from that of BHK-21 cells, as expected. From the same amount of 
BHK-SCR2 total RNA, the amount of L-N joint-containing cDNA obtained was much higher 
than that of L-Gb joint-containing cDNA. This was in keeping with the relative abundance of 
L-N and L-Gb-8-N sub-replicon RNAs as detected using Northern blot analysis described 
above. To reveal the precise locations of the leader-body joints, the cDNAs thus obtained were 
then sequenced as described in Section 2.4.5. As shown in Figure 15, the core sequence of 
SARS-CoV transcription regulatory signal occurred at the junction between the leader and the 
body in each sub-replicon RNA. This strongly suggests that the sub-replicon RNAs are 
generated through the coronavirus-specific discontinuous transcription mechanism and implies 
that the SARS-CoV RNA replication machinery is fully functional in the replicon-carrying 
cells.  
When a replicon-carrying cell is allowed to grow continuously, the average replicon 
copy number per cell as well as the percentage of cells carrying the replicon will decrease with 
increasing generation number if the multiplication rate of the replicon is lower than that of the 
cell. However, if the cells are kept in a medium selective for the presence of replicon, there 
will be an apparent gradual decrease in cell growth rate because the cells having lost the 


















Figure 14. Amplification of sub-replicon RNA regions encompassing leader-body joints by 
RT-PCRs. As indicated, the joint between the leader and GFP-BlaR gene (L-Gb) or that 
between the leader and N gene (L-N) was to be amplified from the total RNA of BHK-21 (Ctrl) 
or BHK-SCR2 (SCR) cells. A 100-bp DNA ladder (Promega) is shown on lane 1, and the sizes 
of selected marker bands are indicated on the left. These DNAs were electrophoresed on a 1% 
agarose gels in TBE, stained with 0.5 µg/ml of EtBr and visualized by irradiation with 
ultraviolet light of 300 nm. The expected sizes of L-Gb- and L-N-containing RT-PCR products 
are approximately 300 bp and 600 bp respectively. The appropriate products are indicated with 
arrows. 





















































Figure 15. Sequences of leader-body joints in SARS-CoV sub-replicon RNAs. (A) L-Gb-8-N. 
(B) L-N. Shown are the sequences of the reverse complement of (or negative-sense) sub-
replicon RNAs. The core sequence of SARS-CoV transcription regulatory signal (GTTCGT in 
reverse complement) is boxed as indicated as TRS. The sequences of the SARS-CoV 5’-leader 








selective medium is an indication of how efficiently the replicon can persist in the cells. 
Throughout the 6 weeks for which the BHK-SCR1 and -SCR2 cultures were maintained under 
blasticidin selection, their growth rates were consistent and practically identical. Their 
doubling time was about 20 hours, which was slightly longer than the doubling time (18 hours) 
of the parent BHK-21 culture. Thus, the SARS-CoV replicon appeared to persist efficiently in 
the cells and the replicon-carrying cell lines were quite stable. 
The persistence efficiency of SARS-CoV replicon in the cells was also studied by 
monitoring the GFP-BlaR gene expression levels in these cells using flow cytometry. As 
shown in Figure 16, the average green fluorescence intensity value of BHK-SCR2 culture was 
about 60 at the end of the third week of cell growth but dropped substantially to about 15 by 
the end of the sixth week. The average green fluorescence intensity value of BHK-SCR2 
culture at the end of the sixth week were in excess of that of the parent BHK-21 culture (about 
4, Figure 16B), indicating that there was still GFP-BlaR gene expression in BHK-SCR2 cells. 
The green fluorescence of the SARS-CoV replicon-carrying cells was also observed at 
different culture times using fluorescence microscopy. Consistent with the flow cytometry data, 
the green fluorescence of the BHK-SCR2 cells noticeably decreased from week 3 to week 6 
(data not shown). At week 6, it was difficult to record the green fluorescent cell images 
because of the low fluorescence intensity. The substantial decrease in green fluorescence 
intensity of BHK-SCR2 cells in three weeks of cell growth indicates the corresponding change 
in the intracellular replicon copy number. Thus, this analysis shows that the SARS-CoV 
replicon does not persist very efficiently in the cells, in contrast to the conclusion drawn from 
the observation of cell growth rate under selection. The ability of BHK-SCR2 cells to grow 
consistently under selection for 6 weeks was most likely due to the possibility that the levels of 
GFP-BlaR protein in most cells during this period of time were still high enough to confer 
blasticidin resistance on the cells, even though they were decreasing. From the flow cytometry 
analysis, it is expected that the cells will lose the SARS-CoV replicon eventually and therefore 
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the SARS-CoV replicon-carrying cell lines are not permanent. Nevertheless, they can persist 
for substantial periods of time and could be good enough to be used for the anti-SARS drug 
screening purpose. 
 
                          
Figure 16. Green fluorescence levels of SARS-CoV replicon-carrying cells at different culture 
times as detected by flow cytometry. Samples of BHK-SCR2 (SCR2) cells were analyzed after 
3 weeks (A) and 6 weeks (B) of growth under blasticidin selection. Samples of the parent 
BHK-21 (BHK) cells were co-analyzed. The results are presented as histograms with green 
fluorescence intensity in exponential scale (horizontal axis) against cell number in linear scale 










In order to provide a convenient and safe system to test potential SARS-CoV 
inhibitors that display antiviral activity against cellular and viral targets involved in viral RNA 
synthesis, including proteases, RNA-dependent RNA polymerase, NTPase/helicase and 
various putative functions that have been identified recently (i.e. poly(U)-specific 
endonuclease, ExoN, S-adenosylmethionine-dependent ribose 2’-O-methyltransferase, 
adenosine diphosphate–ribose 1’’-phosphatase and cyclic phosphodiesterase) (Thiel V, et al., 
2003a), we have established a new strategy that is based on the use of replicon generated by 
reverse genetic technique. The replicon has been designed by the introduction of the 
blasticidin-resistance and GFP fusion gene ownstream of ORF 1 and deletion of most 
structural genes. This strategy enabled us to select for cell lines containing SARS-CoV-derived, 
autonomously replicating RNAs that mediate the expression of GFP as a marker for SARS-
CoV replication. We report here the generation and analysis of the first selectable, SARS-CoV 
based replicon cell line. The SARS-CoV replicon cell line we described here will be a valuable 
tool for the development of anti-SARS therapeutics.  
Within the past fifteen years, the concept of autonomously replicating RNAs (replicon 
RNAs) has been applied in a number of positive-strand RNA virus systems and has led to the 
establishment of novel antiviral screening assays (Bartenschlager, 2002; Frolov et al., 1996; 
Khromykh, 2000; Lo et al., 2003; Randall et al., 2001). Stable cell lines containing non-
cytopathic, selectable replicon RNAs are currently used to assess the efficacy of candidate 
inhibitors of viruses that cannot be propagated efficiently in tissue culture, such as hepatitis C 
virus (Bartenschlager, 2002; Randall et al., 2001). Moreover, since no structural genes and, 
therefore, no infectious viruses are formed, replicon-based assays represent an attractive tool 
for the identification of antivirals if the biosafety of the virus, such as SARS-CoV, is a big 
concern. 
              Our initial ideas to generate a selectable SARS-CoV replicon RNA were based on the 
reports that, as for many positive-strand RNA viruses, only the ORF 1 and the 5’- and 3’-
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genomic termini are needed for autonomous synthesis of the viral genomic RNA. It was 
demonstrated that the ORF 1 products suffice for arterivirus RNA synthesis (Molenkamp et al., 
2000) and sub-genomic RNA synthesis of human coronavirus 229E (Thiel et al., 2001). 
Also some studies (Thiel et al., 2001, 2003b; Almazan et al., 2004; Hertzig et al., 2004) 
demonstrated that the nucleocapsid (N) protein is required for efficient coronavirus genomic 
RNA synthesis. Therefore, this observation has been included in our strategy to establish 
selectable SARS-CoV replicon RNAs. In order to provide a selectable marker gene, we chose 
to use the blasticidin-resistance gene, which has been proven as a functional selection marker 
in screening the blasticidin-resistant stable mammalian cell lines. In addition, the viral gene 
expression in the replicon cell line should be made easily detectable in order to facilitate the 
identification of anti-viral agents. For this purpose, a reporter gene should be included into the 
viral replicon. Thus, the potency of an antiviral agent can be assessed based on its efficiency in 
inhibiting the reporter gene expression from the replicon cell line. The green fluorescence 
protein (GFP) gene has been used for this purpose for many years and should be applicable in 
our replicon. Taken together, a SARS-CoV replicon suitable for use in the identification of 
anti-viral agents should be a wild-type viral genome having the S, E and M genes replaced by 
an antibiotic-selectable gene and a reporter gene. To enable the formation of the sub-replicon 
RNA specific for the translation of each gene on the viral replicon, the TRS will be added or 
retained upstream of each gene and downstream of ORF 1. The overall structure of the SARS-
CoV derived replicon RNA is illustrated in Figure 6. 
 The large size of SARS-CoV genome presented huge obstacles to constructing the 
replicon. First, long RNA sequences make the synthesis of a faithful cDNA molecule difficult, 
because the yield and fidelity of reverse transcriptase and thermophilic DNA polymerases for 
the amplification of cDNA inevitably decreases in proportion to the RNA length. For the 
SARS-CoV replicon to be functional, there cannot be even a single nucleotide deletion or 
insertion in the entire 21-kb ORF 1. Neither is base alteration tolerated in most positions in 
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ORF 1. Second, long RNA sequences are more likely to contain sequences toxic to bacterial 
cells, which make the cDNA sequence in plasmids unstable. It was reported that some 
sequences in ORF 1 of a typical coronavirus are very “toxic” to bacterial cells and therefore 
cannot be cloned at a high copy number (Lai & Holmes, 2001). Also it is difficult to find a 
suitable vector that can accommodate large foreign cDNA inserts. 
 The first difficulty has been overcome largely by the appropriate choice of reagents 
and fine-tuning of RT-PCR procedures. The availability of high fidelity reverse transcriptase 
and thermophilic DNA polymerases has significantly decreased the error rate of RT-PCR. In 
our experiments, the high fidelity Superscript III reverse transcriptase and Elongase 
Polymerase or TripleMaster PCR System were used to minimize the mutations produced in the 
amplification. Our results showed that Superscript III reverse transcriptase can synthesize first-
strand cDNAs of up to 21 kb in sufficient amounts and with good quality. These cDNAs can 
be used as the template to amplify 13 kb PCR products by Elongase Polymerase or 
TripleMaster PCR System. However, to achieve this goal, a number of critical parameters have 
to be kept in mind. First, the integrity of the RNA template is important. Depending on the 
source of the RNA template, a method of preparation should be chosen that minimizes 
degradation of the RNA. Second, the conditions of the reverse transcription reaction influence 
the outcome of the subsequent PCR. Previous studies have shown that amplification of long 
RNAs requires digestion of the RNA with RNaseH after the first-strand cDNA synthesis 
(Nathan et al., 1995). Therefore, this reaction was included in our procedure. Third, as is the 
case for all PCRs, the cycle conditions have to be optimized according to the amount of 
template, the PCR primers, and the cycle profile. Last but not the least, the polymerase plays 
critical role in our long range PCR reaction. In our experiments, we tested most of the long-
range PCR polymerases which are commercial available, only TripleMaster PCR System could 
amplify the first half 13 kb of SARS-CoV genome efficiently and specifically. Also Elongase 
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Polymerase was used to amplify the remaining 12.6 kb recombinant BCGbN replicon cDNA 
because of its good yield and relatively cheap price.  
 The second difficulty is that the viral cDNA contains sequences toxic to bacterial cells 
and thus prevents its cloning. Solutions to the poison sequence problems have been made 
previously. For example, the cDNA copy of yellow fever virus RNA could not be cloned in 
one piece; therefore, it was cloned in two segments and then ligated in vitro to make a full-
length cDNA for in vitro transcription (Rice et al., 1989). Thus, the passage of poison 
sequences in bacteria was avoided. This approach has been adopted for the rapid cloning of 
some important coronaviruses, for example, MHV, TGEV and SARS-CoV (Yount et al., 2000; 
Yount et al., 2002; Yount et al., 2003). We have been trying to use this method to assemble 
SARS-CoV replicon cDNA. A number of regions in SARS-CoV genome were found to be 
toxic to E. coli strains that are regularly used for DNA cloning (data not shown). This sequence 
toxicity was circumvented by disruption of toxic domains and the use of tolerant bacterial 
strains. We have got cDNA clones that cover the whole SARS-CoV genome. Inevitably, there 
are numerous base alterations in those clones. We are in the process of reverting the base 
alterations in these clones. Once this process is completed, the cloned cDNAs can be used to 
assemble the SARS-CoV replicon. Recently, the successful use of the single-copy bacterial 
artificial chromosome (BAC) vector to clone the entire coronavirus genomic cDNA has been 
reported (Almazan et al., 2000). We also tried this method but it did not work. All the clones 
that we have obtained had random deletions in different regions and none of them contained 
the full-length replicon cDNA. Realizing the potential difficulties and tardiness in cloning 
SARS-CoV sequences, we decided to simultaneously embark on a “quick and dirty” approach 
that avoids cloning altogether – assembling the SARS-CoV cDNAs directly. This method is 
“dirty” because a large proportion of replicon thus produced should carry base alterations. 
However, we reasoned that as long as there are a minute number of functional replicon 
molecules, the host cells carrying them can be selected for and amplified based on the 
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antibiotic-resistance conferred by the replicon. For this purpose, substantial amount (tens of 
micrograms) of SARS-CoV replicon cDNA was needed to generate the viral replicon cell line. 
To generate such a large amount of cDNA with as few mutations as possible, it is necessary to 
minimize the rounds of PCR and maximize the yield of PCR product. From our experiences, it 
is critical to use at least 10 µg of “dirty” replicon RNA preparation (Figure 10 and its 
description in the text) to transfect BHK-21 cells in one well of a standard 6-well plate. 
Otherwise no positive colonies could be selected out. After transfection and around two weeks’ 
selection, a few colonies grew up and SARS-CoV-derived replicon cell lines were created 
successfully.  
 A weakness of our “quick and dirty” approach is that it is relatively expensive. 
Replicon cDNAs have to be synthesized in a large amount and are consumed with use. 
However, this strategy is the fastest way to assemble large genes and genomes of any RNA or 
DNA virus. For any newly emerging viral pathogens, effective biodefense and control requires 
rapid response. Time, rather than money, is the biggest concern. Therefore, our strategy is very 
suitable for combating newly emerging RNA or DNA viral pathogens. 
             Another weakness of our replicon cell-based system is that the structural genes S, E 
and M are not included in the replicon RNA. Therefore, it cannot be used to screen for drugs 
that act on cellular and viral targets involved in receptor binding, virus entry, genome 
encapsulation and virus release. However, this weakness may not be significant because the 
structural genes of coronavirus change rapidly and therefore anti-viral agents that target these 
genes may have less consistent efficacy. On the other hand, ORF 1 is the most conserved 
region in coronavirus genome and therefore the most consistent and favorable targets of anti-
viral agents (Holmes et al., 2003a). 
            Our established SARS-CoV replicon cell line could be used to test potential SARS-
CoV ORF 1 inhibitors. A biochemical agent that inhibits viral RNA synthesis, translation or 
proteolytic processing of viral proteins will suppress the expression of the reporter gene in the 
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replicon cells. With an easily detectable GFP expression and the absence of virion production, 
the viral replicon cell line represents a simpler and safer system for anti-viral agent 
identification than a live virus infection system. Thus, the efficacy of candidate inhibitors can 
be evaluated by measuring the fluorescence intensity of the replicon cells before and after the 
adding of the drugs. That means our cell-based system is easy to be automated and used in the 
large-scale screening of anti-SARS-CoV agents. Furthermore, the application of the viral 
replicon cell-based system can be used to test individual antiviral agents designed based on 
certain biochemical principles or the drugs targeting at multiple regions of the SARS-CoV 
ORF 1 or N gene. Since no infectious virus is formed, the assay represents a safe protocol that 
can be performed in biosafety level 2 laboratories.  
 Compared to anti-viral agent identification systems based on purified proteins or 
nucleic acids, our SARS-CoV replicon cell line has two advantages: first, if a candidate 
inhibitor can inhibit the replication of our replicon RNA, which occurs inside the replicon cells, 
it also means that this agent can enter into the cell; second, the cytotoxicity of a candidate 
inhibitor can be observed simultaneously by viewing the cell morphology directly. Two critical 
indexes of a candidate inhibitor – the inhibitory effect and the cytotoxicity can therefore be 
observed all at once using our SARS-CoV replicon cell line. For an anti-viral agent identified 
using a purified-bimolecular-based system, further tests on cell delivery and cytotoxicity of the 
agent have to be done separately. 
 Our SARS-CoV replicon could be used as a vector for heterologous gene expression. 
The unique transcriptional strategy of coronaviruses makes them promising candidates for the 
development of versatile multigene RNA vectors (Bredenbeek et al., 1992; Enjuanes et al., 
2001). First, the expression of heterologous genes can be achieved in the context of the 
coronavirus genome, a helper-dependent minigenome or an autonomous replicating sub-
genomic RNA. In each case, it has been shown that it is possible to insert a transcriptional 
cassette (which is comprised of a TRS element located upstream of an ORF of interest) and 
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that transcriptional functions provided in trans are able to mediate the synthesis of a sub-
genomic RNA encoding the protein of interest (Alonso et al., 2002; Curtis et al., 2002; Fischer 
et al., 1997). We have constructed a SARS-CoV replicon RNA that simultaneously mediates 
the expression of one reporter protein and one structural protein. This indicates that our SARS-
CoV replicon should provide a vector system for the incorporation and expression of one or 
more foreign genes. Second, the size of the coronavirus RNA genome implies a large cloning 
capacity for the insertion of heterologous genes. In theory, about one-third of the SARS-CoV 
genome, or around 9 kb, could be replaced by one or more foreign genes. Third, although we 
do not yet fully understand the parameters that govern TRS element activity, it is clear that 
different TRS elements, or modified TRS elements, could be used to regulate the levels of 
heterologous gene expression. Thus, it appears that coronavirus-based vector systems might be 
useful for the simultaneous, differential expression of multiple genes. Our Northern blot results 
showed that the abundance of the sub-replicon RNA for ORF 8 translation (L-8-N) was 
unexpected high, even higher than that of L-N, in the replicon-carrying cells (Figure 13). The 
relative abundance of the sub-genomic RNA for ORF 8 translation is much lower in SARS-
CoV-infected cells (Thiel et al, 2003a). Thus, the deletion of SARS-CoV genomic sequence 
and/or the inclusion of GFP-BlaR gene sequence between ORFs 1 and 8 somehow induces the 
synthesis of L-8-N sub-replicon RNA. ORF 8 is not essential for replicon RNA synthesis. Our 
replicon may therefore be used as a high-level gene expression vector if a foreign gene is 
inserted in place of ORF 8. As shown in Figure 16, the expression levels of the GFP-BlaR 
reporter gene in the current replicon cell lines may be somewhat too low to be used for anti-
SARS drug identification. For such a drug identification purpose, an improved replicon can be 
constructed by the inclusion of an additional reporter gene in place of ORF 8 in the current 
replicon. Fourth, RNA replicon expression systems based on positive-strand RNA viruses have 
an advantage comparing with DNA vector: the synthesis of the RNA takes place in the 
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cytoplasm without a DNA intermediary, excluding the possibility of an inadvertent 
chromosomal integration of foreign genetic material.  
We have successfully inserted and expressed GFP-BlaR gene from the SARS-CoV 
associated replicon, demonstrating the feasibility of using SARS-CoV based replicon vectors 
for heterologous gene expression. Efficient synthesis of recombinant replicon RNA in the cell 
was demonstrated by GFP expression, the presence of leader-containing sub-replicon RNA, 
and the blasticidin resistance of the replicon cell lines. Our data demonstrated that BHK-21 
cells carrying the replicon were able to survive and maintain expression of foreign genes for 
more than one month. Cell lines carrying the replicon underwent cell division at a rate similar 
to that of the parent cell line indicating that the replicon causes little disturbance of 
fundamental host cell functions. Thus the replicon might be considered for applications where 
long-term expression and prolonged survival of the host cells are required. Taken together, the 
efficient replicon RNA synthesis, absence of cytotoxicity, and expression of an antibiotic 
resistance gene allowing simple and efficient selection of replicon-expressing cells make our 
replicon a unique and useful addition to existing RNA virus expression systems. 
 The study of replicons has greatly enhanced the understanding of RNA synthesis of 
members of the coronavirus family. The reporter gene activity of a coronavirus replicon is 
translated from both the RNA transfected into cells and the progeny molecules produced by 
RNA synthesis. Therefore, the use of replicons allows the study of both virus RNA synthesis 
and translation, two steps in the virus life-cycle tightly coordinated in vivo in space and time. 
Characterization of individual gene functions involved in coronavirus RNA synthesis is still at 
a very early stage. Therefore, our replicon design, replicon template synthesis and assembly 
protocols, and replicon-carrying cell line selection protocol enable us to study the involvement 
of individual trans-acting ORF 1 domains and cis-acting elements in RNA synthesis. Also the 
SARS-CoV replicon provides a tool for exploring the possible functions of some unknown 
genes by serially deleting certain genes or intentionally introducing mutations at certain 
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positions or introducing random mutations and finding out which occur in persisting replicons. 
It has been reported that the TRSs of TGEV genes are essential for mediating a 100- to 1,000-
fold increase in sub-genomic RNA synthesis when it is located in the appropriate context 
(Alonso et al., 2002).  Our SARS-CoV replicon could be used in studying the extent of the 
TRSs in regulating the expression of sub-replicon RNAs. To this end, mutagenesis studies at 
the TRS region upstream of ORF 8 in the replicon could be performed to define the sequences  
that cause high expression of L-8-N sub-replicon RNA.  
 Our SARS-CoV replicon cell line can also be used to study the development of drug 
resistance in the virus. Because of the low fidelity of viral RdRp, coronavirus replicon is 
undergoing mutation all the time in the cell, as reported recently (Hertzig et al., 2004). It is 
suggested that these observed nucleotide changes in the replicon may represent adaptive 
mutations necessary for continuous replication in selected cell lines (Hertzig et al., 2004). So, 
once an efficient inhibitor of replicon persistence is identified, the replicon cell line can be 
used further to select for rare cells that are resistant to the identified inhibitor. The replicon 
RNA can be isolated from the resistant cells and sequenced to identify the marker mutations 
related to drug resistance. The detection of such mutations would provide valuable information 
on the viral target protein(s) and the mechanism of inhibition. The functions of certain viral 
genomic domains can also be elucidated from this kind of analysis. 
 In conclusion, this study describes the first replicon system for a highly pathogenic 
SARS-CoV and a rapid protocol for developing this system. The replicon system provides a 
convenient and safe assay for the identification of anti-SARS-CoV agents. The protocols and 
reagents developed in this study will be useful for gaining insights into the mechanisms of 
RNA synthesis of this pathogen. Potential additional applications include the development of 
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Appendix 1 Primer Names & Sequences 
Name  Sequence (5’ to 3’) 
 
02R  GCTGAGGCACCAAATTCCAG 
04F  GAATGAGGTCTCATCTCAAGAGCTTTGAAGAAAGTGC 
06F  GAATGAGGTCTCACCCTTGATTCTTATCCAGCTCTTG 
06R  GAATGAGGTCTCACGAAGCTCACTATAAGAAATAGAACCC 
07F  CTATGAGGTCTCATTCGTCCAGACACTCGTTATGTG 
08R  TGCCCACAATTTAGAAGATGACTC 
09F  TTCTTAGGCTATTGTTGCTGCTGC 
09R  GATTCAGGTCTCATTGTCCTCCACTTGCTAGGTAATCC 
10F  GAATGAGGTCTCAACAACCAATCACCAACTGTGTGAAG 
10R  GAATCAGGTCTCATCCTCTAGTGGCGGCTATTGAC 
11R  TGGGAGGCTTATGTGACTTGC 
12F  GTGCCTGTATTAGGAGACCATTCC 
12R  GAATGAGGTCTCATGGTATGCCTGGTATGTCAACAC 
13F  GAATGTGGTCTCAACCAAAGGACATGACCTACCGTAG 
13R  GAATGTGGTCTCTACTGTTGAATAATGCCGTCTACTTTC 
14F  GAATGAGGTCTCACAGTTGCCTGAAACCTACTTTACTCAG 
14R2  GTATCAGGTCTCAATGTTCGTTTAGTTGTTAACAAGAATATCAC 
16R2  GCCCCGCGGTCATTCTCCTAAGAAGCTATTAAAATCACATGG 
1R  TGCGGAGTCGAGTTTCAATGTTTG 
2R  GGTTTGCTGCATCAAGTGTGCG 
3F  TACCAAGGGAAAGCCCGTAAAAGG 
3R  CTTAACCTCCCGCAGGGATAAGAGAC 
4F   GGCTGGCTCTTACAGAGATTGGTCC 
4FX  CTGCAAAGCGAGTTCTTAATGTGGTG 
4RX  GCAGAAAGACACGCAATCATAATCAATG 
5F  CCATTCAGGATGGTGTCACTCGTG 
5FX  TTTGTCCGTATCCAACCTGGTCAAAC 
6F   GCAGATCAGGCTATGACCCAAATGTAC 
6R  AACTCAGGTTCCCAGTACCGTGAGG 
8F  GCTCTGATAAAGGAGTTGCACCAGGTAC 
9R  GTCATTCTCCTAAGAAGCTATTAAAATCACATGG 
A1R  GAATCAGCTCTTCATGGTAATGGTTGAGTTGGTACAAGG 
BBIBlF  CCAGGATCCGGTCTCTGTAAACGAACATGCCTTTGTCTCAAGAAGAATCCACCCTC 
BGBF  CGTGGATCCGGTCTCTACATGGCCTCCAAAGGAGAAGAAC 
BGBR CCAGAATTCGGTCTCACCAATTAGCCCTCCCACACATAACCAG 
GAPDHF  ACGCCTGCTTCACCACCTTCTTG 
GAPDHR  GGAGCCAAAAGGGTCATCATCTCTG 
GFPBLAR  CTGTACATAACCTTCGGGCATGGC 
NFX  CATTCAGGTCTCATTGGTTTTCACTCGAAATCCAGGATC 
NR  CCGCCTCTGCTTCCCTCTGC 
SAP1R  CAACCATCCATGATATGAACATAGC 
SAP1R2  GCCGACGCTCTTCAATATGCCTGCTGACAACAATGGTG 
SAP2F   CCGTTTCTGCAATGGTTAGGATG 
SAP2R  GGCTGCTGTAGTCAATGGTATGATG 
SCVD3709RP GAGAATGCTTTCTTGCCATTTACTC 
SCVD555RP GCTTCTGTGTACTACAGTCAGCTGATG 







SP4251R  TCTTCCTTAGCATTAGGTGCTTC 
SP6081F  CAGACTTGAATGGCGATGTAG  
T71+F  CACGCTCTTCAGCATACTAATACGACTCACTATAGATATTAGGTTTTTACCTACCCAGGAAAAG 
T71+F3  TAATACGACTCACTATAGATATTAGGTTTTTACCTACCCAGGAAAAG 
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Appendix 2 Reagents for Northern Blotting 
All solutions were prepared using RNase-free water and fresh AnalaR grade reagents. 
 
5 x MOPS 
To make 1 L: 
Item                                                      Amount                                      Source 
MOPS                                                 20.60 g                                        Sigma 
NaAC                                                  5.44 g                                          Merck 
0.5 M EDTA                                       10 ml                                           NUMI, NUS 
800 ml of water was added and pH was adjusted to 7.0 using sodium hydroxide. Solution was 
then topped to 1 L and sterilized by membrane filter through a 0.22 µm filter. 
 
Denaturing Sample Buffer 
Item                                                      Amount                                           Source 
Ambion Sample Buffer II                    75 µl                                                 Ambion     
5 × MOPS Buffer (pH= 7.0)                30 µl                                                Appendix 2 
37% Formaldehyde                              24 µl                                                Merck 
Glycerol                                                6 µl                                                  Merck  
 
Alkaline solution  
To make 1 L: 
Item                                                      Amount                                              Source 
NaOH                                                     2 g                                                    Merck 
NaCl                                                       5.84 g                                               Merck 
Solution was then topped to 1 L and sterilized by membrane filter through a 0.22 µm filter. 
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Neutralization solution  
12.11 g Tris (Fisher Biotech) was dissolved in 800 ml water and pH was adjusted to 7.5 using 




To make 100 ml: 
Item                                                      Amount                                        Source 
20× SSC Stock Solution                       25 ml                                           NUMI, NUS 
Liquid block                                          5 ml                                            Amersham 
10% (w/v) SDS                                     1 ml                                            NUMI, NUS 
Dextran sulphate                                   5 g                                              Sigma 
All the components were combined and topped up to 100ml. The hybridization buffer was 
stored in suitable aliquots at -20°C. 
 
Buffer A 
12.11 g Tris (Fisher Biotech) and 17.52g NaCl were dissolved in 800 ml water and pH was 
adjusted to 9.5 using NaOH. The solution was then topped to 1 L and sterilized by membrane 








Anti-fluorescein-AP conjugate solution 
0.05 g bovine serum albumin fraction V (Amresco) was dissolved in 10 ml Buffer A and 2 µl 
anti-fluorescein-AP conjugate (Amersham) was then added.   
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AP Wash Buffer 
3 ml of Tween 20 (DAKO) was diluted in 997 ml of Buffer A (Appendix 2) to make 1 L of AP 
wash buffer. 
 
 
